<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS190885</article-id><article-id pub-id-type="doi">10.1101/2023.11.07.566012</article-id><article-id pub-id-type="archive">PPR754955</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Predicting human and viral protein variants affecting COVID-19 susceptibility and repurposing therapeutics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Waman</surname><given-names>Vaishali P.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ashford</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lam</surname><given-names>Su Datt</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sen</surname><given-names>Neeladri</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Abbasian</surname><given-names>Mahnaz</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Woodridge</surname><given-names>Laurel</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Goldtzvik</surname><given-names>Yonathan</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bordin</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jiaxin</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sillitoe</surname><given-names>Ian</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Orengo</surname><given-names>Christine A</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><aff id="A1"><label>1</label>Institute of Structural and Molecular Biology, University College London, London, WC1E 6BT, UK</aff><aff id="A2"><label>2</label>Department of Applied Physics, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Bangi, Malaysia</aff></contrib-group><author-notes><corresp id="CR1">
<label>*</label>Corresponding author <email>c.orengo@ucl.ac.uk</email>
</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>10</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>08</day><month>11</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">The COVID-19 disease is an ongoing global health concern. Although vaccination provides some protection, people are still susceptible to re-infection. Ostensibly, certain populations or clinical groups may be more vulnerable. Factors causing these differences are unclear and whilst socioeconomic and cultural differences are likely to be important, human genetic factors could influence susceptibility. Experimental studies indicate SARS-CoV-2 uses innate immune suppression as a strategy to speed-up entry and replication into the host cell. Therefore, it is necessary to understand the impact of variants in immunity-associated human proteins on susceptibility to COVID-19.</p><p id="P2">In this work, we analysed missense coding variants in several SARS-CoV-2 proteins and its human protein interactors that could enhance binding affinity to SARS-CoV-2. We curated a dataset of 19 SARS-CoV-2: human protein 3D-complexes, from the experimentally determined structures in the Protein Data Bank and models built using AlphaFold2-multimer, and analysed impact of missense variants occurring in the protein-protein interface region. We analysed 468 missense variants from human proteins and 212 variants from SARS-CoV-2 proteins and computationally predicted their impacts on binding affinities to SARS-CoV-2 proteins, using 3D-complexes.</p><p id="P3">We predicted a total of 26 affinity-enhancing variants from 14 human proteins implicated in increased binding affinity to SARS-CoV-2. These include key-immunity associated genes (TOMM70, ISG15, IFIH1, IFIT2, RPS3, PALS1, NUP98, RAE1, AXL, ARF6, TRIMM, TRIM25) as well as important spike receptors (KREMEN1, AXL and ACE2). We report both common (e.g., Y13N in IFIH1) and rare variants in these proteins and discuss their likely structural and functional impact, using information on known and predicted functional sites. Potential mechanisms associated with immune suppression implicated by these variants are discussed.</p><p id="P4">Occurrence of certain predicted affinity-enhancing variants should be monitored as they could lead to increased susceptibility and reduced immune response to SARS-CoV-2 infection in individuals/populations carrying them. Our analyses aid in understanding the potential impact of genetic variation in immunity-associated proteins on COVID-19 susceptibility and help guide drug-repurposing strategies.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>human genetic variation</kwd><kwd>SARS-CoV-2: human protein interaction</kwd><kwd>protein structure complex</kwd><kwd>Functional Family</kwd><kwd>CATH database</kwd><kwd>protein binding affinity prediction</kwd><kwd>immunity</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P5">The COVID-19 pandemic has caused a major global health and socioeconomic burden since 2020. Many countries are still experiencing an intermittent rise in the number of infections due to emergence of new Variants of Concern (VOCs) of SARS-CoV-2 and their sub-variants [<xref ref-type="bibr" rid="R1">1</xref>]. Although vaccines are now available, re-infection is common [<xref ref-type="bibr" rid="R2">2</xref>]. Various factors including ethnicity, age and clinical conditions have been proposed to be associated with an increased risk of infection [<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R10">10</xref>]. In addition, increasing reports indicate that human genetic variation is a contributing factor for increased susceptibility and disease severity [<xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R13">13</xref>].</p><p id="P6">Potential drug targets include human host proteins which interact with SARS-CoV-2 [<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref>]. In 2020, Krogan group identified a total of 332 human proteins that interact with SARS-CoV-2 proteins, using affinity purification followed by mass spectrometry (AP-MS) [<xref ref-type="bibr" rid="R15">15</xref>]. Subsequently, the presence of additional human proteins interactors of SARS-CoV-2 was also revealed by other studies based on techniques such as yeast two-hybrid assay, anti-tag coimmunoprecipitation, tandem affinity purification, pull down, structure-based studies (X-ray, NMR), etc. (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/intact/home">https://www.ebi.ac.uk/intact/home</ext-link>) [<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R16">16</xref>–<xref ref-type="bibr" rid="R19">19</xref>] and are made available via dedicated protein-interaction resources such as IntAct [<xref ref-type="bibr" rid="R20">20</xref>] and BIOGRID [<xref ref-type="bibr" rid="R21">21</xref>]. These studies indicate that interactor proteins in humans participate in a wide range of biological processes/pathways, including innate and adaptive immune pathways, lipid metabolism, cell adhesion, mRNA processing, among others [<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R22">22</xref>].</p><p id="P7">Innate immune suppression is known as one of the key characteristics of infections by SARS-CoV-2 and its VOCs. SARS-CoV-2 VOCs (namely Alpha, Beta, Gamma, Delta, and Omicron) are reported to exhibit increased interferon resistance as compared to the wild -type suggesting evasion of innate immunity is a driving force for SARS-CoV-2 evolution [<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R24">24</xref>]. Furthermore, inborn variation in immunity-associated genes is reported to trigger susceptibility to COVID-19 [<xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R26">26</xref>]. For example, rare variants in the Toll-like receptor 7 gene have been associated with increased severity and susceptibility of the COVID-19 [<xref ref-type="bibr" rid="R12">12</xref>]. Likewise, various studies including those by the GeNOMICC-ISARIC consortium suggests association of both common and rare variants with increased severity of COVID-19 [<xref ref-type="bibr" rid="R27">27</xref>–<xref ref-type="bibr" rid="R32">32</xref>].</p><p id="P8">Though spike-ACE2 binding is the key entry mechanism used by SARS-CoV-2 for cell entry and infection, recent experimental studies indicate that SARS-CoV-2 also uses innate immune suppression as a strategy to speed-up entry and replication in the host cell [<xref ref-type="bibr" rid="R33">33</xref>, <xref ref-type="bibr" rid="R34">34</xref>]. Interactions such as SARS-CoV-2:ORF9b-human:TOMM70 and SARS-CoV-2:NSP1-human:NUP98 have been associated with innate immune evasion [<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R35">35</xref>]. Further experimental studies have suggested involvement of other human protein interactors of SARS-CoV-2 associated with the immunity-associated pathways (e.g., IFIH1, ISG15, IFIT2) [<xref ref-type="bibr" rid="R33">33</xref>, <xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R36">36</xref>].</p><p id="P9">In the case of SARS-CoV-2, spike-ACE2 is the most studied protein complex, where the impact of emerging variants in spike as well as natural human population variants in hACE2 have been computationally predicted by the Barton group and others [<xref ref-type="bibr" rid="R37">37</xref>–<xref ref-type="bibr" rid="R40">40</xref>]. Some of these predicted variants in ACE2 and spike protein, have also been validated experimentally [<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R40">40</xref>]. In this study, we focus on the impact of variants in immune-associated proteins and novel spike receptors (such as AXL and Kremen1) in humans on their binding to SARS-CoV-2 proteins. Such analyses could explain novel mechanisms by which SARS-CoV-2 proteins interfere with natural immune pathways and disrupt the system in humans.</p><p id="P10">Computationally predicted (docking-based) complexes for a subset of interactions identified from the Krogan study, are made available via several resources [<xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R42">42</xref>]. The Beltrao group has designed a resource called mutfunc, which has predicted impacts of all possible single-amino acid substitutions in SARS-CoV-2 proteins, using known 3D structure data (<ext-link ext-link-type="uri" xlink:href="http://sars.mutfunc.com/home">http://sars.mutfunc.com/home</ext-link>, [<xref ref-type="bibr" rid="R43">43</xref>]). Likewise, Ascher group developed the COVID-3D resource, to analyse &gt; 11,000 SARS-CoV-2 variants and predicted the impact of missense variants using spike-ACE2 complex [<xref ref-type="bibr" rid="R39">39</xref>]. More recently, a powerful AlphaFold2-based protein structure prediction method has been developed for modelling protein-protein complexes which facilitates modelling of interactions between SARS-CoV-2 and human proteins which have yet to be experimentally characterized, and with improved accuracy compared to other approaches [<xref ref-type="bibr" rid="R44">44</xref>–<xref ref-type="bibr" rid="R48">48</xref>].</p><p id="P11">In this study, we analysed the impact of missense coding variants in human and viral proteins occurring at protein-protein interface, using a curated dataset of 19 immune-associated SARS-CoV-2: human protein 3D-complexes, obtained from the Protein Data Bank [<xref ref-type="bibr" rid="R49">49</xref>] and models built using AlphaFold2-multimer [<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R46">46</xref>]. For the human proteins, we obtained population variants from various databases including gnomAD ([<xref ref-type="bibr" rid="R50">50</xref>] <ext-link ext-link-type="uri" xlink:href="https://gnomad.broadinstitute.org">https://gnomad.broadinstitute.org</ext-link>) and GenomeAsia100k [<xref ref-type="bibr" rid="R51">51</xref>]. For the viral proteins, we obtained mutation data from ViralZone (https://viralzone.expasy.org/), CoV-Glue (https://cov-glue.cvr.gla.ac.uk/) and COG-UK (<ext-link ext-link-type="uri" xlink:href="https://sars2.cvr.gla.ac.uk/cog-uk/">https://sars2.cvr.gla.ac.uk/cog-uk/</ext-link>) [<xref ref-type="bibr" rid="R52">52</xref>–<xref ref-type="bibr" rid="R54">54</xref>]. The impact of variants on binding affinity of the complexes was computationally predicted using a state-of-the-art program (mCSM-PPI2) [<xref ref-type="bibr" rid="R55">55</xref>]. The structural and functional impact of the predicted affinity-enhancing variants was analysed in the context of proximity to known functional sites such as protein-protein interface, ligand or substrate -binding sites and predicted sites identified using conserved positions in Functional Families in the CATH database (i.e., CATH-FunFams) [<xref ref-type="bibr" rid="R56">56</xref>–<xref ref-type="bibr" rid="R58">58</xref>]. CATH-FunFams represent functionally coherent groups i.e., members of a CATH-FunFam have high structural similarity and function [<xref ref-type="bibr" rid="R56">56</xref>]. Finally, the human proteins implicated in enhanced SARS-CoV-2 binding are mapped onto protein networks to understand biological pathways/processes associated with the network modules. We then studied whether these proteins are associated with CATH-FunFams that are enriched in small molecules or drugs from ChEMBL [<xref ref-type="bibr" rid="R59">59</xref>, <xref ref-type="bibr" rid="R60">60</xref>].</p><p id="P12">In summary, we analysed the impact of missense coding variants occurring at protein-protein interfaces in a total of nineteen 3D complexes of human proteins and SARS-CoV-2 interactors. A total of 26 affinity-enhancing variants from 14 human proteins (namely TOMM70, IFIH1, IFIT2, ISG15, RPS3, PALS1, NUP98, RAE1, AXL, ARF6, KREMEN1, TRIMM, TRIM25 and ACE2) were predicted to enhance binding affinity to their interacting proteins in SARS-CoV-2. Our study sheds light on affinity-enhancing variants in immunity-associated proteins; their frequencies in gnomAD populations; their impact on protein structure and function and the populations more likely to be susceptible to COVID-19 infection. We provide computational evidence that the predicted affinity-enhancing variants in human proteins could promote binding to SARS-CoV-2 proteins, instead of their natural protein partners or substrates in immune pathways, thereby hampering the normal antiviral activity and leading to increased susceptibility. Protein Functional families associated with three proteins (IFIH1, AXL and ARF6) are associated with small molecule inhibitors and their potential applications in drug-repurposing in discussed.</p></sec><sec id="S2" sec-type="materials | methods"><title>Materials and methods</title><sec id="S3"><title>Compilation of interactors associated with SARS-CoV-2 immunity</title><p id="P13">The dataset of human proteins interacting with SARS-CoV-2 proteins, was compiled using the COVID-19 UniProtKB resource ([<xref ref-type="bibr" rid="R61">61</xref>]; <ext-link ext-link-type="uri" xlink:href="https://covid-19.uniprot.org/uniprotkb?query=*">https://covid-19.uniprot.org/uniprotkb?query=*</ext-link>) and IntAct database ([<xref ref-type="bibr" rid="R20">20</xref>]; <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/intact/home">https://www.ebi.ac.uk/intact/home</ext-link>). IntAct provides a COVID-19 dataset of SARS-CoV-2: human protein interactors which is based on interactions reported from experimental studies. For every protein-protein interaction, IntAct assigns an MIscore (ranges from 0 to 1) based on (i) the type of the experimental detection method (ii), the number of associated publications and (iii) the interaction types (such as direct association, physical association). The IntAct recommended MIscore threshold of 0.45 was used to exclude low-confidence interactions [<xref ref-type="bibr" rid="R62">62</xref>].</p><p id="P14">Thus, the dataset of a total of 536 high-confidence (MI-score &gt; 0.45) interactions are considered for subsequent analyses. We further filtered immunity-associated human proteins by mapping specific GO terms associated with immunity using UniProt (i.e.,GO:0002250 GO:0002218, GO:0002376, GO:0045087, GO:0045089, GO:0060337, GO:0050776 and GO:0006955)[<xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R63">63</xref>]; and by mapping the UniProt IDs to InnateDB database (<ext-link ext-link-type="uri" xlink:href="http://innatedb.sahmri.com/">http://innatedb.sahmri.com/</ext-link> [<xref ref-type="bibr" rid="R64">64</xref>]. We also curated available literature-based evidence specifying COVID-19-associated immunological role associated with interacting pair of proteins in dataset.</p></sec><sec id="S4"><title>Functional families in the CATH database and conserved functional sites</title><p id="P15">The CATH database provides a hierarchical structural classification of protein domains into Class (C), Architecture (A), Topology (T) and Homologous Superfamily (H). In CATH, protein domains are classified into superfamilies where there is strong evidence of an evolutionary relationship via structure and sequence similarity [<xref ref-type="bibr" rid="R65">65</xref>, <xref ref-type="bibr" rid="R66">66</xref>]. Within each superfamily, sequences are sub-classified using an entropy-based method to segregate functionally coherent subgroups known as Functional Families (CATH-FunFams) [<xref ref-type="bibr" rid="R56">56</xref>]. The conserved sites obtained from CATH-FunFams have been shown to be enriched in known protein functional sites [<xref ref-type="bibr" rid="R56">56</xref>, <xref ref-type="bibr" rid="R57">57</xref>].</p><p id="P16">For the dataset of shortlisted human proteins and their SARS-CoV-2 interactors, we identified CATH-FunFams, and subsequently conserved sites as follows:</p><list list-type="bullet" id="L1"><list-item><p id="P17">Identification of CATH-FunFams:</p><p id="P18">We scanned the sequences of human and their interacting SARS-CoV-2 proteins against HMMs of FunFams in CATH v4.3 (<ext-link ext-link-type="uri" xlink:href="https://www.cathdb.info/">https://www.cathdb.info/</ext-link>), using HMMsearch (e-value &lt; 1e<sup>-3</sup>) [<xref ref-type="bibr" rid="R67">67</xref>]. We then processed the output of HMMsearch using cath-resolve-hits, an in-house tool built to obtain the best non-overlapping set of domain matches [<xref ref-type="bibr" rid="R67">67</xref>, <xref ref-type="bibr" rid="R68">68</xref>].</p></list-item><list-item><p id="P19">Identification of conserved sites using CATH-FunFams:</p><p id="P20">Using the matching CATH-FunFams, we identified conserved sites using Scorecons, an entropy-based method [<xref ref-type="bibr" rid="R69">69</xref>]. The multiple sequence alignment (MSA) program, namely MAFFT is used to construct an MSA from seed sequences within a FunFam [<xref ref-type="bibr" rid="R68">68</xref>]. The Scorecons program is then applied to each MSA to determine an overall measure of sequence diversity called Diversity of Positions score (DOPs). DOPs captures the amount of diversity in an MSA by considering all the different conservation scores, and their frequencies, and provides a value from 0 (i.e., zero diversity) and 100 (i.e., high diversity). Only MSAs with a DOPs score <underline>&gt;</underline> 70 were considered for further analyses. The Scorecons program also provides the degree of conservation of each position in the MSA. Thus, for each column in a CATH-FunFam based MSA, the Scorecons program provides a conservation score ranging from 0 (i.e., not conserved) to 1 (i.e., completely conserved). The sites belonging to alignment positions with Scorecons-based score &gt;= 90 are used for analyses and are referred to as Scorecons90 in this manuscript.</p></list-item></list></sec><sec id="S5"><title>Compilation of missense coding variants in human and SARS-CoV-2 proteins</title><list list-type="bullet" id="L2"><list-item><p id="P21">Human protein variants:</p><p id="P22">For the human genes, missense coding variants from canonical transcripts were obtained from the Genome Aggregation Database (gnomAD, v2.1.1; the recommended version for coding region analyses) (<ext-link ext-link-type="uri" xlink:href="https://gnomad.broadinstitute.org/">https://gnomad.broadinstitute.org/</ext-link>) [<xref ref-type="bibr" rid="R50">50</xref>]. We compiled ancestry (i.e., ethnic population) information available from gnomAD, using VarSite [<xref ref-type="bibr" rid="R70">70</xref>]. GnomAD provides ancestry for the following populations: African/African American (afr), American Admixed/Latino (amr), Amish (ami), Ashkenazi Jewish (asj), East Asian (eas), South Asian (sas), Finnish (fin) and Non-Finnish European (nfe). If individuals did not unambiguously cluster with any of these populations in a principal component analysis (PCA), gnomAD classifies them as "other" (oth). GnomAD v2 also provides sub-continental information for the East Asian cohort (Japanese, Koreans) and Non-Finnish European (Bulgarian, Estonian, Swedish, North-Western European, Southern European) populations.</p></list-item><list-item><p id="P23">SARS-CoV-2 protein variants:</p><p id="P24">For each of the associated interactor proteins in SARS-CoV-2, a non-redundant set of mutations in strains of SARS-CoV-2 (including VOCs and Variants of Interest) was compiled from resources such as ViralZone [<xref ref-type="bibr" rid="R54">54</xref>], COG-UK ([<xref ref-type="bibr" rid="R52">52</xref>] <ext-link ext-link-type="uri" xlink:href="https://sars2.cvr.gla.ac.uk/cog-uk/">https://sars2.cvr.gla.ac.uk/cog-uk/</ext-link>), and CoV-Glue (<ext-link ext-link-type="uri" xlink:href="https://cov-glue-viz.cvr.gla.ac.uk/">https://cov-glue-viz.cvr.gla.ac.uk/</ext-link>) [<xref ref-type="bibr" rid="R53">53</xref>].</p></list-item></list></sec><sec id="S6"><title>Functional site data from CATH-FunVar (Functional Variation) protocol</title><p id="P25">All gnomAD missense variants in the interactor human genes were processed using a modified version of the in-house FunVar protocol to identify variants occurring near known and predicted functional sites. Predicted sites comprise CATH-FunFam-based conserved residues, i.e., highly conserved residues identified by the Scorecons program (i.e., Scorecons90 sites, as described above).</p><p id="P26">Known functional sites were compiled from existing resources and include: known ligand and nucleic acid binding sites from BioLip [<xref ref-type="bibr" rid="R71">71</xref>]; protein-protein interface (PPI) residues from PDBSum [<xref ref-type="bibr" rid="R72">72</xref>]; catalytic sites annotated in M-CSA and VarMap [<xref ref-type="bibr" rid="R73">73</xref>, <xref ref-type="bibr" rid="R74">74</xref>] and annotated functional sites in UniProt resource.</p><p id="P27">Spatial proximity of each gnomAD variant to these sites was found by mapping each variant to a representative domain from the corresponding FunFam in CATH v4.3. Functional sites were similarly mapped to FunFam representative domains, allowing detection of variants occurring on or near (within 5Å) of any of the functional sites.</p><p id="P28">For each variant, the Grantham score (<ext-link ext-link-type="uri" xlink:href="https://gist.github.com/danielecook/501f03650bca6a3db31ff3af2d413d2a">https://gist.github.com/danielecook/501f03650bca6a3db31ff3af2d413d2a</ext-link>) was calculated to identify variants having a significant change in physico-chemical properties (such as volume, polarity), as compared to that of wild-type residues.</p><p id="P29">Finally, each variant was assigned a simple functional impact score (from 1 to 5) by counting each of the impacts - scoring 1 for each of: high Grantham score; variant is a catalytic site; variant lies on a known functional site; variant near (5Å) a known site; variant is on a conserved predicted (Scorecons90) site. Additionally, CATH-FunVar reports impact scores from CADD [<xref ref-type="bibr" rid="R75">75</xref>] and SIFT [<xref ref-type="bibr" rid="R76">76</xref>].</p></sec><sec id="S7"><title>Three-dimensional (3D) structures of complexes</title><p id="P30">3D structures of complexes are available for 10 interactions as follows- human:TOMM70-SARS-CoV-2:ORF9b [PDB ID: 7KDT], human:ISG15-SARS-CoV-2:PLpro [7RBS], human:RPS2-SARS-CoV-2:NSP1 [6ZMT], hRPS3- SARS-CoV-2:NSP1 [6ZMT], human:Ubiquitin- SARS-CoV-2:Plpro [7RBR], human:APOA1- SARS-CoV-2:ORF3a, human:PALS1-SARS-CoV-2:E, human:NUP98-SARS-CoV-2:ORF6 [7VPH] and humanRAE1- SARS-CoV-2:ORF6 [7VPH] and human:ACE2- SARS-CoV-2:spike [wild-type (6M0J, 7A95); Alpha (7EDJ), Beta (7V7Z), Gamma (7V83), Delta (7V89), Omicron (7T9K), BA.1 (7XO6), BA.2(7XB0, 7XO8), BA.3(7XB1)].</p><p id="P31">For the remaining interactions with no available structures of complexes in the PDB, we predicted models using AlphaFold2-ptm and AlphaFold2-multimer(v1) [<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R46">46</xref>], as described below.</p><list list-type="bullet" id="L3"><list-item><p id="P32">Modelling complexes using AlphaFold2-ptm and AlphaFold2-multimer:</p><p id="P33">Prior to modelling protein-protein complexes, we excluded some interactions from the modelling procedure due to the following reasons – we excluded proteins of very short lengths such as ORF3b (22aa residues long) and proteins for which high-quality models are not built by AlphaFold2 (<ext-link ext-link-type="uri" xlink:href="https://alphafold.ebi.ac.uk/">https://alphafold.ebi.ac.uk/</ext-link>).</p><p id="P34">We modelled the remaining complexes using the AlphaFold2-ptm and alphafold-multimer(v1) protocols, which were made available in March, 2022 ([<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R77">77</xref>]; <ext-link ext-link-type="uri" xlink:href="https://github.com/sokrypton/ColabFold">https://github.com/sokrypton/ColabFold</ext-link>]. We built models using both the AlphaFold2_ptm and AlphaFold2-multimer(v1) methods and then selected a model from one of these methods, whichever had the best interface quality (see <xref ref-type="sec" rid="S19">results</xref>, <xref ref-type="table" rid="T1">table 1</xref>).</p><p id="P35">High-confidence models were chosen where models have overall pLDDT (predicted local difference distance test) <underline>&gt;</underline> 70 as well as pTM-Score (predicted TM-score) <underline>&gt;</underline> 70 [<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R46">46</xref>]. We further filtered complexes on the basis of the interface quality i.e., interface-pLDDT (i.e., those with &lt;70 were excluded) and interface-PAE (predicted alignment error &gt;10 were excluded) and by manually inspecting the domain interface regions (i.e., excluded models where we observed erroneous overlapping/entangled interface). We performed additional quality checks such as verifying interface stability score using PIZSA method (which calculates protein interaction Z-Score; &gt; 1.5 indicates stable interface) [<xref ref-type="bibr" rid="R78">78</xref>] and predicted binding affinity of the complexes by the PRODIGY method [<xref ref-type="bibr" rid="R79">79</xref>]. The resultant high-confidence models predicted in this study along with their quality metrics are given in results section, <xref ref-type="table" rid="T1">Table 1</xref>.</p></list-item><list-item><p id="P36">Extraction of interface residues using complexes</p><p id="P37">After the selection of the complexes, we extracted interface residues as follows:</p></list-item><list-item><p id="P38">Directly-contacting (DC) residues</p><p id="P39">For the PDB complexes, we extracted directly-contacting (DC) interface residues made available by PDBSum [<xref ref-type="bibr" rid="R72">72</xref>]. PDBSum calculates the protein-protein interfaces using the NACCESS program (<ext-link ext-link-type="uri" xlink:href="http://www.bioinf.manchester.ac.uk/naccess/">http://www.bioinf.manchester.ac.uk/naccess/</ext-link>). For the modelled complexes, we extracted interface residues by selecting residues from interacting chains with heavy atom distances &lt;=4Å) [<xref ref-type="bibr" rid="R80">80</xref>, <xref ref-type="bibr" rid="R81">81</xref>]. Human protein missense variants in gnomAD that occur in DC interface residues are referred to as ‘DC-variant’ residues.</p></list-item><list-item><p id="P40">Secondary shell residues</p><p id="P41">Residues that occur within 5Å from the DC interface are considered to be residues in the secondary shell and variants at these residue positions are likely to influence binding [<xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R82">82</xref>] and are referred to as ‘DCSS-variants’.</p></list-item></list></sec><sec id="S8"><title>Predicting the impact of variants in human and viral proteins on the binding affinity of the complexes</title><p id="P42">For the filtered dataset of complexes (experimental and predicted), we applied the mCSM-PPI2 program [<xref ref-type="bibr" rid="R55">55</xref>] to identify human and viral missense variants which could significantly impact binding-affinity of interacting proteins. We analysed the impact of missense variants reported in gnomAD that occur at directly contacting interface (DC-variant) and secondary shell (DCSS-variant) residues.</p><p id="P43">The mCSM-PPI2 program, developed by the Ascher lab, was shown to be the top-performing method when compared to 26 other methods in CAPRI (round 26) blind tests [<xref ref-type="bibr" rid="R55">55</xref>]. mCSM-PPI2 is based on a graph-based structural signature framework with evolutionary information, inter-residue non-covalent interaction networks analysis plus computed energetic terms, providing an optimised overall prediction performance. It was used to predict change in binding affinity (i.e., mCSM-PPI2 ΔΔG<sup>Affinity</sup> in kcal/mol) for each mutation.</p><p id="P44">A positive mCSM-PPI2 ΔΔG<sup>Affinity</sup> score (&gt; 0 Kcal/mol) indicates that the mutation is stabilising the interaction whereas a negative ΔΔG score (&lt; 0 Kcal/mol) indicates a destabilising effect [<xref ref-type="bibr" rid="R55">55</xref>]. Where available, we compiled evidence from experimental studies reporting experimental mutagenesis and binding affinity kinetic assays [<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R37">37</xref>] to choose our ΔΔG thresholds. For example, in the case of spike-ACE2 complex, the mutations K26R in ACE2 and S477N in the spike protein are reported to increase the binding affinity of the spike-ACE2 complex using kinetic assays [<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R38">38</xref>], and these are predicted to have mCSM-PPI2 ΔΔG affinity of 0.12 Kcal/mol and 0.5 Kcal/mol respectively. Likewise, experimental alanine scanning mutagenesis studies in the ORF9b-TOMM70 complex indicates that a E477A mutation in TOMM70 and a S53A mutation in ORF9b significantly reduced the binding affinity of the interaction [<xref ref-type="bibr" rid="R14">14</xref>], and are predicted to have a mCSM-PPI2 ΔΔG<sup>Affinity</sup> of &lt; -0.5 Kcal/mol. Therefore, we used the confidence cut-offs of ΔΔG<sup>Affinity</sup> <underline>&lt;</underline> -0.5 Kcal/mol (for destabilising; affinity-reducing) and <underline>&gt;</underline> 0.5 Kcal/mol (for stabilising; affinity-enhancing), to analyse the structural impact of gnomAD variants in this study, while we also provide a catalogue of other mutations predicted to have scores ranging from 0 to 0.490 Kcal/mol (see <xref ref-type="sec" rid="S19">results</xref> section). Through <italic>in silico</italic> saturation mutagenesis, we further confirmed that the mCSM-PPI2 method does not show bias towards predicting positive ΔΔG<sup>Affinity</sup> scores and corresponds well to observed changes in amino acid properties for mutated residues.</p><sec id="S9"><title>Analysis of predicted affinity-enhancing variants</title><p id="P45">As the affinity-enhancing variants could be associated with increased risk of susceptibility/infection, we closely examined their 3D structural impact on molecular interactions and characterised these variants in the context of known and predicted functional sites (See FunVar section above) and using the UniProt’s site annotations. Variants are mapped on 3D-complexes and visualized using UCSF Chimera [<xref ref-type="bibr" rid="R80">80</xref>]. We further analysed their associated population allele frequencies in gnomAD as well as other databases such as Indigenomes [<xref ref-type="bibr" rid="R83">83</xref>], SweGen [<xref ref-type="bibr" rid="R84">84</xref>], GenomeAsia100k [<xref ref-type="bibr" rid="R51">51</xref>], jMORP [<xref ref-type="bibr" rid="R85">85</xref>] and the NIH-funded research hub called All of Us ([<xref ref-type="bibr" rid="R86">86</xref>] <ext-link ext-link-type="uri" xlink:href="https://databrowser.researchallofus.org/">https://databrowser.researchallofus.org/</ext-link>). Finally, we analysed pathogenicity scores by mutpred2, CADD and SIFT for affinity-enhancing variants. These methods were chosen as the study by Pejaver group showed that Mutpred2 performs better than other predictors while CADD and SIFT were the second and third best performing tools [<xref ref-type="bibr" rid="R87">87</xref>].</p></sec></sec><sec id="S10"><title>Network mapping and enrichment analysis</title><list list-type="bullet" id="L5"><list-item><p id="P46">Identification of network modules</p><p id="P47">The human proteins containing affinity-enhancing variants with putative impact on SARS-CoV-2 binding, were mapped to ConsensusPathDB (CPDB) and STRING database (STRINGdb) protein-protein interaction networks [<xref ref-type="bibr" rid="R88">88</xref>, <xref ref-type="bibr" rid="R89">89</xref>]. Interactions from STRINGdb were filtered to include only those with confidence values &gt;=0.2 to optimize signal-to-noise ratio. A module detection algorithm (M1) was applied to the network using the MOdularising NEtwork Toolbox that adopts a multiresolution approach to combine optimization algorithms to improve modularity [<xref ref-type="bibr" rid="R90">90</xref>].</p><list list-type="bullet" id="L6"><list-item><p id="P48">Enrichment analyses</p><p id="P49">Pathway enrichment analysis was performed using g:profiler (<ext-link ext-link-type="uri" xlink:href="https://biit.cs.ut.ee/gprofiler/gost">https://biit.cs.ut.ee/gprofiler/gost</ext-link>, [<xref ref-type="bibr" rid="R91">91</xref>]), a public webserver using Ensembl and Ensembl Genomes to identify significantly enriched terms in Gene Ontology (GO) biological processes, KEGG and Reactome databases [<xref ref-type="bibr" rid="R92">92</xref>–<xref ref-type="bibr" rid="R94">94</xref>]. Pathways were ranked by significance (p&lt;0.01) and the most significant term per database for the protein or each module was taken as the representative pathway. Where necessary, Ensembl identifiers with the most GO annotations were selected according to the default g:profiler function. Values and pathways for STRINGdb and CPDB modules were retained.</p></list-item></list></list-item></list></sec><sec id="S11"><title>Identification of druggable functional families in CATH database</title><p id="P50">The human proteins with affinity-enhancing variants, were mapped to the CATH functional families (CATH-FunFams) that are linked with small molecule information from ChEMBL [<xref ref-type="bibr" rid="R59">59</xref>, <xref ref-type="bibr" rid="R60">60</xref>]. For the associated human proteins, the druggability score of the protein-protein interface region was analysed using the CavityPlus program [<xref ref-type="bibr" rid="R95">95</xref>].</p><p id="P51">The methodology used in the study is summarised in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p></sec></sec><sec id="S12" sec-type="results"><title>Results</title><sec id="S13"><title>Dataset of SARS-CoV-2: human protein interactors, 3D-complexes and missense variants</title><p id="P52">As previously described (see <xref ref-type="sec" rid="S2">Methods</xref>), from 536 high-confidence (MIscore <underline>&gt;</underline> 0.45) protein-protein interactions, we curated 94 human proteins involved in SARS-CoV-2 infection and immunity by identifying those with immunity-associated GO terms. For the curated dataset of 94 human proteins, we compiled information from multiples sources: the interactor protein in SARS-CoV-2, IntAct MIscore [<xref ref-type="bibr" rid="R20">20</xref>], UniProt accession IDs [<xref ref-type="bibr" rid="R61">61</xref>], immune-associated GO terms, literature evidence linked to the interaction in IntAct, literature-based evidence for COVID-19 immune association, CRISPR-association (obtained from BIOGRID-ORCS; <ext-link ext-link-type="uri" xlink:href="https://orcs.thebiogrid.org/">https://orcs.thebiogrid.org/</ext-link> [<xref ref-type="bibr" rid="R21">21</xref>]) and gene-expression (obtained from SARS-COVIDB; <ext-link ext-link-type="uri" xlink:href="https://sarscovidb.org/">https://sarscovidb.org/</ext-link> [<xref ref-type="bibr" rid="R96">96</xref>]). This information is provided in <xref ref-type="supplementary-material" rid="SD1">Supplementary files 1 and 2</xref>.</p><p id="P53">In total, the 94 human proteins were associated with 110 SARS-CoV-2:human interactions (<xref ref-type="supplementary-material" rid="SD1">Supplementary file 2</xref>). Experimental 3D structures for 10 interactions were available in the PDB, with a further 9 high-quality models predicted using AlphaFold2-multimer/ptm method, as summarised in <xref ref-type="table" rid="T1">Table 1</xref>. Thus, a total of 19 protein 3D structural complexes were used for subsequent analyses.</p><p id="P54">For the human proteins from this curated dataset of 19 complexes (<xref ref-type="table" rid="T1">Table 1</xref>), we analysed a total of 468 missense variants from gnomAD; that occur at directly contacting (DC) residues in the interface of the complexes (DC-variants, 131 in total) as well as those that occur within 5Å from the DC residues i.e., secondary shell (DCSS-variants, 337 in total).</p><p id="P55">A total of 26 variants from 14 human proteins, are predicted to significantly enhance binding affinity to their SARS-CoV-2 protein partners by the mCSM-ppi2 program (ΔΔG<sup>Affinity</sup> <underline>&gt;</underline> 0.5 kcal/mol), as detailed in the <xref ref-type="table" rid="T2">Table 2</xref>.</p><p id="P56">For the affinity-enhancing variants (ΔΔG<sup>Affinity</sup> scores <underline>&gt;</underline> 0.5 Kcal/mol) from the 14 human proteins (<xref ref-type="table" rid="T2">Table 2</xref>), we analysed their impact on protein structure and function and their allele frequency distribution related to distinct populations in the gnomAD database and other databases including GenomeAsia100K (see <xref ref-type="sec" rid="S2">methods</xref>). Most of the predicted affinity-enhancing variants are rare in gnomAD populations, while a few affinity-enhancing variants are observed to be common in genes such as IFIH1 and ISG15 (See figure in <xref ref-type="supplementary-material" rid="SD1">Supplementary file 3</xref>).</p><p id="P57">For the 14 human proteins, affinity-enhancing variants were analysed in the context of proximity to known and predicted functional sites (<xref ref-type="supplementary-material" rid="SD1">Supplementary file 4</xref>). The potential mechanisms associated with suppression of the immune system implicated by these variants are discussed in the following section, using some complexes to illustrate our approach.</p></sec></sec><sec id="S14"><title>Structure-function analyses of predicted affinity-enhancing variants</title><sec id="S15"><label>1</label><title>Impact of human TOMM70 variants on SARS-CoV-2: ORF9b binding</title><p id="P58">TOMM70 protein is one of the major human import receptors in the translocase of the outer membrane (TOM) complex. It recognizes and mediates the translocation of mitochondrial preproteins from the cytosol into the mitochondria in a chaperone(HSP90)-dependent manner [<xref ref-type="bibr" rid="R97">97</xref>]. It is involved in activation of the innate immune system [GO:0002218] and interacts with ORF9b, which is a key viral innate immune antagonist in SARS-CoV-2 [<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R97">97</xref>, <xref ref-type="bibr" rid="R98">98</xref>]. A study by the Krogan group revealed that TOMM70 is a high-confidence interactor of SARS-CoV-2 ORF9b indicating that binding of ORF9b to the C-terminal domain of TOMM70 is associated with suppression of the innate immune response [<xref ref-type="bibr" rid="R33">33</xref>]. We analysed the impact of missense variants using the experimental structure of this complex (PDB ID: 7KDT [<xref ref-type="bibr" rid="R14">14</xref>]).</p><sec id="S16"><title>Affinity-enhancing variants: structural-function impact and population distribution</title><p id="P59">Three DC (directly contacting)-variants in TOMM70 (V556L, K576R, A591T) and two DCSS-variants (V514I, A483T) were predicted to significantly increase affinity (ΔΔG<sup>Affinity</sup> <underline>&gt;</underline> 0.5 Kcal/mol) (<xref ref-type="table" rid="T3">Table 3</xref> and <xref ref-type="fig" rid="F2">Figure 2</xref>).</p><p id="P60">The variant V556L has the highest predicted change in the binding affinity (ΔΔG<sup>Affinity</sup> score of 0.905 Kcal/mol). V556 is a directly contacting (DC_PPI) residue at the ORF9b:TOMM70 interface. The wild type V556 in TOMM70 forms hydrophobic bonds with A68 and F69 in ORF9b, and a polar interaction with T72. The mutant V556L gains additional hydrophobic bonds with A68 and F69, resulting in increased predicted affinity for SARS-CoV-2: ORF9b.</p><p id="P61">The DCSS-variant at residue position 483 lies close to (i.e., within 5Å) the phosphorylation site in SARS-CoV-2: ORF9b i.e., S53, which is important for binding of ORF9b to TOMM70. The formation of TOMM70:ORF9b complex is regulated via phosphorylation at S53 [<xref ref-type="bibr" rid="R99">99</xref>]. A483 also interacts with other DC residues in TOMM70. The A483T mutation strengthens this interaction, and this mutation is predicted to be strongly pathogenic by mutpred2 (score =0.90). <xref ref-type="fig" rid="F2">Figure 2</xref> summarizes impact of all affinity-enhancing variants and their structural impact on atomic interactions at the interface.</p><p id="P62">Most affinity-increasing variants in TOMM70 are observed in the African American and American population, but with rare allele frequency i.e., less than 1% (<xref ref-type="table" rid="T3">Table 3</xref>). Most of the affinity-enhancing variants have an impact on atomic interactions of residues in the interface and are also predicted to have significant impact by various programs including CADD (score &gt; 20), SIFT (predicted as deleterious) and predicted to be pathogenic by mutpred2 (score &gt;0.5), as shown in <xref ref-type="fig" rid="F2">Figure 2(B)</xref>.</p></sec></sec><sec id="S17"><label>2</label><title>Impact of human IFIH1 variants on SARS-CoV-2: PLPro binding</title><p id="P63">PLpro (papain-like cysteine protease) in SARS-CoV-2 is involved in a wide range of important functions, such as viral polyprotein chain processing, dysregulation of host inflammatory responses, and impairing the type I interferon (IFN-1) antiviral immune responses [<xref ref-type="bibr" rid="R100">100</xref>]. SARS-CoV-2: PLpro plays a key role in innate immune suppression in humans by interacting with various host substrates such as ISG15, IFIH1 and IFIT2, and others [<xref ref-type="bibr" rid="R101">101</xref>, <xref ref-type="bibr" rid="R102">102</xref>]. Therefore, the SARS-CoV-2:PLpro is a hot spot for designing protein-protein interactor inhibitors [<xref ref-type="bibr" rid="R102">102</xref>].</p><p id="P64">IFIH1 (also known as MDA5) is a cytoplasmic innate immune receptor. IFIH1 is a pattern-recognition receptor which binds to viral RNAs and suppresses translation initiation [<xref ref-type="bibr" rid="R103">103</xref>]. IFIH1-binding to viral RNA is known to induce type I interferon response by triggering activation of antiviral immunological genes including IFN-alpha, IFN-beta and pro-inflammatory cytokines [<xref ref-type="bibr" rid="R103">103</xref>–<xref ref-type="bibr" rid="R105">105</xref>]. SARS-COV-2 employs PLpro to bind and block the activation of an IFIH1-dependent cascade of antiviral responses [<xref ref-type="bibr" rid="R104">104</xref>]. PLpro is suggested to bind CARD domains of IFIH1 [<xref ref-type="bibr" rid="R101">101</xref>, <xref ref-type="bibr" rid="R104">104</xref>] and hence we modelled a complex of PLpro and IFIH1 using AlphaFold2-multimer (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p><sec id="S18"><title>Affinity-enhancing variants: structural impact and population distribution</title><p id="P65">Two affinity-enhancing variants in IFIH1 are predicted - both Y13N and S16L, are DC residues (<xref ref-type="fig" rid="F3">Figure 3</xref>). According to gnomAD, Y13N is a common variant [allele frequency (AF) &gt; 1%] in East Asians. This is in accordance with GenomeAsia100K, which indicates Y13N is a common variant in Northeast Asian i.e., in Japanese (AF= 0.01) and Korean populations (AF = 0.003). Upon mutation Y13N, hydrophobic interactions between aromatic rings of Y13 in wild-type IFIH1 and of P245, P246 and Y262 in viral PLpro are replaced by a stronger hydrogen bond between the N13 of the mutant IFIH1 and the P246 of PLpro (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p><p id="P66">The other variant significantly impacting SARS-CoV-2:PLpro binding affinity is S16L, observed to occur at a rare frequency in Europeans (non-Finnish). The side chain oxygen atom on residue S16 of IFIH1 forms two weak polar interactions with Y266 of PLpro whereas the leucine side chain in the S16L IFIH1 mutant interacts more strongly with Y266 (<xref ref-type="fig" rid="F3">Figure 3b</xref>). Leucine side chain forms a hydrogen bond with viral Y266 and hydrophobic and polar interaction with Y262 (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p></sec></sec><sec id="S19"><label>3</label><title>Impact of human ISG15 variants on SARS-CoV-2: PLPro binding</title><p id="P67">ISG15 (Interferon stimulated gene 15) plays a key role in the innate immune response to viral infection via a process known as ISGylation upon activation by type I interferons or by viral/bacterial infections. ISGylation (ISG15 modification) is a process whereby ISG15 protein covalently binds to other protein substrates [<xref ref-type="bibr" rid="R100">100</xref>, <xref ref-type="bibr" rid="R106">106</xref>]. The ISGylation process acts as an antiviral defence mechanism against SARS-CoV-2 and several other RNA viruses. SARS-CoV-2 PLpro binds to ISG15 and block the ISGylation [<xref ref-type="bibr" rid="R104">104</xref>, <xref ref-type="bibr" rid="R106">106</xref>, <xref ref-type="bibr" rid="R107">107</xref>]. ISG15 binds to PLpro via LRGG motif (154-157 residues).</p><sec id="S20"><title>Affinity-enhancing variants: structural impact and population distribution</title><p id="P68">Two ISG15 coding variants at DC positions (S21N, L121N) are predicted to enhance the binding affinity of the ISG15-PLpro complex (<xref ref-type="table" rid="T4">Table 4</xref>, <xref ref-type="fig" rid="F4">Figure 4</xref>).</p><p id="P69">L121Q, one of the direct contact residues in the interface, is predicted to enhance the ISG15: SCoV2 PLpro binding affinity (mCSM-PPI2 ΔΔG<sup>Affinity</sup> = 0.57 kcal/mol). This variant occurs within 5Å from the key LRGG motif (the PLpro recognition site) and forms direct interaction with R153, which is adjacent to this motif, which is therefore likely to have impact on PLpro-binding. Analyses using conserved sites using Scorecons indicates that the variant lies in the structural neighbourhood (5Å) from five conserved residues (at positions 117, 120, 122, 123 and 152; with Scorecons90) of which one (W123) is also predicted to be an allosteric site (score: 0.896, predicted using Ohm [<xref ref-type="bibr" rid="R108">108</xref>]). This substitution is only observed in the Swedish population at rare frequency.</p><p id="P70">The second DC-variant S21N is annotated in ClinVar (ID: 475283, benign) and is associated with Mendelian susceptibility to mycobacterial diseases (also known as Immunodeficiency 38 disease)[<xref ref-type="bibr" rid="R109">109</xref>]. The variant is associated with severe clinical disease upon infection with weakly virulent mycobacteria (including Mycobacterium bovis and Bacille Calmette-Guerin vaccines) [<xref ref-type="bibr" rid="R110">110</xref>, <xref ref-type="bibr" rid="R111">111</xref>]. The S21N variant is predicted to moderately increase affinity (with the borderline mCSM-PPI2 ΔΔG<sup>Affinity</sup> score of 0.401 Kcal/mol)) and is a common variant (allele frequency &gt;1%) found in the African population, as supported by multiple population databases including gnomAD [allele frequency (AF): 0.01648], GenomeAsia100K (allele frequency 0.043269) and AllofUs (allele frequency 0.014).</p><p id="P71">In the case of affinity-reducing (protective) variants (mCSM-PPI2 ΔΔG<sup>Affinity</sup> <underline>&lt;</underline> -0.05 Kcal/mol), four variants (R155Q, R155Q, N151D, L85P, M23T) were predicted with significantly reduced binding affinity (ΔΔG<sup>Affinity</sup>&lt;-1.0 Kcal/mol). Most of these occur only in Non-Finnish Europeans and one predominantly in the American population (R155W). Two variants (R155Q, R155W) occur within the known PLpro-recognition motif in ISG15 (LRGG motif formed by 154-157 residues) [<xref ref-type="bibr" rid="R106">106</xref>]. Thus, individuals carrying these mutations may be at lower risk of compromised immunity mediated by ISG15: PLpro binding.</p></sec></sec><sec id="S21"><label>4</label><title>Impact of human IFIT2 variants on SARS-CoV-2: PLPro binding</title><p id="P72">IFIT2 (Interferon-induced protein with tetratricopeptide repeats 2) is an RNA-binding protein, and binding of RNA is known to be important for antiviral activity of IFIT2 [127]. Biochemical studies indicate that human IFIT2 binds to SARS-CoV-2:PLpro [101], however an experimental structure of the complex is not available. The modelled complex in our study, indicates SARS-CoV-2: PLpro binds at a channel-like region at the C-terminus of IFIT2, which is a known RNA-binding region (formed by K37, R184, K255, R259, R291, and K410) [128]. Three PLpro-interacting residues in IFIT2 (i.e., R259, K410 and R291) are involved in RNA-binding (depicted in <xref ref-type="fig" rid="F5">Figure 5</xref>).</p><sec id="S22"><title>Affinity-enhancing variants: structural impact and population distribution</title><p id="P73">Four IFIT2 DCSS-variants (L373F, K221E, A319S and A319T) significantly affect the binding affinity (mCSM-PPI2 ΔΔG<sup>Affinity</sup> <underline>&gt;</underline> 0.5 Kcal/mol) (see <xref ref-type="table" rid="T5">Table 5</xref>). Three of these-A319S, A319T and L373F are also predicted to be pathogenic by CADD (score <underline>&gt;</underline> 20) and SIFT scores. Two DCSS-variants in IFIT2 namely, K221E and A319(S/T) are predominant in South Asian and African/AA populations, respectively. The residues (K221E, A319S and A319T and Y383F) directly interact with residues (R259 and R291) known to be involved in the RNA-binding in IFIT2 (<xref ref-type="fig" rid="F5">Figure 5B</xref>). Thus, mutations in IFIT2 protein which increase binding to SARS-CoV-2 PLpro are likely to hinder the binding of IFIT2 to RNA, and thus the normal antiviral mechanism of IFIT2.</p><p id="P74">Thus, our analyses of 3D complexes, affinity-enhancing variants, and functional sites identifies some affinity enhancing variants that could promote the binding of host immune proteins to SARS-CoV-2 proteins, thereby reducing the binding to their natural protein partners. This could mediate reduced immune responses in certain individuals.</p></sec></sec><sec id="S23"><title>Impact of variants in SARS-CoV-2 proteins</title><p id="P75">In addition to human protein variants, we also analysed the impact of viral protein variants, in Spike-RBD, Spike-NTD, PLPro, ORF9b, ORF7b, ORF6, ORF3a, NSP7, NSP15, NSP14, NSP1, N and E (using experimental/predicted complexes listed in <xref ref-type="table" rid="T1">Table 1</xref>). However, a few variants in SARS-CoV-2 proteins such as NSP14 (L6074F and N6054I), PLpro (L1774F) and Spike (S477N) are predicted to be affinity-enhancing (mCSM-PPI2 ΔΔG<sup>Affinity</sup> <underline>&gt;</underline> 0.5 Kcal/mol). The impact of the variant spike-RBD S477N on enhanced ACE2-binding affinity is recently confirmed by experimental assays [<xref ref-type="bibr" rid="R37">37</xref>].</p></sec></sec><sec id="S24"><title>Pathway enrichment analyses</title><p id="P76">We examined the biological processes and signalling pathways associated with the 14 human proteins containing affinity-enhancing variants (<xref ref-type="table" rid="T2">Table 2</xref>) using three well-established pathway enrichment databases: Gene Ontology (GO), KEGG and Reactome (<xref ref-type="table" rid="T6">Table 6</xref>). The most significantly enriched terms were related to immune functions, including viral life cycle (GO biological process) and Influenza A (KEGG). The top enriched Reactome pathway was SARS-CoV-2 Infection, confirming the association with this panel of proteins identified in earlier analyses.</p><p id="P77">Since many biological processes are governed by functional modules which are highly interconnected sub-networks of protein-protein interactions, identifying functional modules containing the 14 human proteins provides a method for gaining further insights into their biological functions. This approach can also offer insights into specific mechanisms contributing to SARS-CoV-2 pathology.</p><p id="P78">To this end, we used two state-of-the-art modularity detection algorithms and applied them to two well regarded network datasets: STRING, and ConsensusPathDB. We then identified which modules contain any of the 14 genes and performed pathway enrichment analysis on each of the modules using GO (biological processes), KEGG and Reactome. The enrichment analysis was used to assign to each of the 14 genes the appropriate biological processes/pathways. For a full list of genes in each module, see <xref ref-type="supplementary-material" rid="SD1">supplementary file 5 and 6</xref>.</p><p id="P79">Unsurprisingly, many of the 14 genes were associated with immune response to viral infection, including interferon-inducible genes IFIT2 and IFIH1, and ISG15 involved in modulating viral replication. Induction by type I interferons (α/β), which activate other immune cells, was also associated with the transmembrane protein TRIM25.</p><p id="P80">Several symptoms, particularly in severe or long COVID-19 cases, are associated with mitochondrial dysfunction, including cytokine storms [<xref ref-type="bibr" rid="R112">112</xref>], which is a key pathway associated with TOMM70 associated with mitochondrion organisation. It has also been found to be involved in interferon regulation [<xref ref-type="bibr" rid="R113">113</xref>]. SARS-CoV-2 viral proteins replicate in the cytoplasm via translation on ribosomes, hence supporting our identification of several pathways involved in cytoplasmic or ribosomal transport, specifically NUP98, RAE1, ribosomal protein RPS3, TOMM70 and TRIM25. Other genes are involved in cell processes that are hijacked by the virus during infection. For example, ARF6 was identified as involved in exocytosis, but is used by the virus to infiltrate and infect the cell [<xref ref-type="bibr" rid="R114">114</xref>]. Overall, the findings of our functional analysis highlight some key mechanisms involved in the viral response to COVID-19.</p><sec id="S25"><title>Functional families associated with small molecule inhibitors</title><p id="P81">For the 14 human proteins containing predicted affinity-enhancing variants, we analysed their associated functional families in CATH to inspect whether any of the homologous proteins in the FunFam were linked to known small molecule inhibitors. These small molecules, which may include drug-like molecules or approved drugs, were identified using the ChEMBL database (see <xref ref-type="table" rid="T7">Table 7</xref>).</p><p id="P82">Next, we used CavityPlus to detect druggability of the protein-protein interface formed by these three proteins. CavityPlus provided strong confidence for prediction for druggability of IFIH1: PLpro interface and ARF6:NSP15-interface, and medium confidence for AXL:NTD interface (see <xref ref-type="supplementary-material" rid="SD1">supplementary file 7</xref>). These results are indicative of potential applications of their associated inhibitors for designing drugs targeting these protein-protein interactions.</p><p id="P83">For example, IFIH1 is associated with Selgantolimod in ChEMBL (ID: CHEMBL4594258), which is in phase 2 clinical trial. Selgantolimod is known to be a Toll Like Receptor 8 Agonist, which increases immune responses in chronic Hepatitis B patients (Reyes et al., 2019). Analyses using CavityPlus provided a strong prediction score for the presence of two cavities that occur at IFIH1-PLpro interface (the topmost cavity with score of 4177.0, <xref ref-type="supplementary-material" rid="SD1">Supplementary File 7</xref>). These cavities do not interfere with CARD oligomerization or its protein partner MAVS, which is required for IFIH1-induced interferon response, thus substantiating the potential use of this molecule in designing therapeutics against SARS-CoV-2 infection. Docking of this ligand with IFIH1-PLpro, provides support for binding at this cavity ([<xref ref-type="bibr" rid="R115">115</xref>]; see <xref ref-type="supplementary-material" rid="SD1">Supplementary File 8</xref>).</p><p id="P84">Likewise, cavities the interface of NTD-AXL and ARF6-NSP15 could likely be interesting targets for drug design and further experimental assays are required to substantiate their application for drug repurposing or as starting points for structure-based design of novel compounds.</p></sec></sec><sec id="S26" sec-type="discussion"><title>Discussion</title><p id="P85">We analysed ˜20% of SARS-CoV-2 immunity associated interactions using structural data of protein-protein complexes. Structural analyses helped in predicting affinity-enhancing variants in immunity-associated proteins and their impact on SARS-CoV-2-human protein complexes and COVID-19 susceptibility. Detection of putative affinity-enhancing variants in human proteins and information on their proximity to functional sites in the 3D structure can aid in explaining potential mechanisms associated with the suppression of normal functioning of immune proteins, thereby affecting COVID-19 susceptibility.</p><p id="P86">We applied a structural bioinformatics approach to analyse the impact of missense variants from human and viral proteins, using 19 SARS-CoV-2: human protein complexes (obtained from PDB or built using AlphaFold2-multimer/ptm). We analysed 468 coding variants in human proteins occurring at protein-protein interfaces. A total of 26 affinity-enhancing variants from 14 human proteins were predicted to significantly enhance SARS-CoV-2 binding.</p><p id="P87">A majority of these human proteins were involved in key immune pathways and associated with antiviral activity against SARS-CoV-2, including Interferon stimulating genes (ISG15, IFIT2); important receptors (such as IFIH1, TOMM70); proteins involved in nucleocytoplasmic shuttling of viral mRNA (NUP98 and RAE1), proteins involved in cellular translation machinery (RPS2 and RPS3) and cell entry receptors via spike-binding (ACE2, KREMEN1 and AXL). Among these 14 proteins, experimental assays have been performed on spike-ACE2, substantiating the role of the predicted spike affinity-enhancing variants in COVID-19 susceptibility and transmission [<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R38">38</xref>], while variants in the remaining proteins are reported for the first time in this study.</p><p id="P88">The modelling of complexes using AlphaFold2-multimer/ptm helps to provide structural insights into the mechanisms of SARS-CoV-2 binding and increased the structural coverage of the complexes. We propose that affinity-enhancing variants in key-immunity associated human proteins could promote their binding to SARS-CoV-2 proteins, competing with protein partners or substrates in immune pathways, and this in turn, may have an impact on COVID-19 susceptibility. This finding is in line with previous experimental studies on SARS-CoV-2: human interactions that affect natural immune pathways [<xref ref-type="bibr" rid="R116">116</xref>, <xref ref-type="bibr" rid="R117">117</xref>]. For example. Li et al. [<xref ref-type="bibr" rid="R117">117</xref>] suggest that binding of SARS-CoV-2: ORF6 to human: NUP98-RAE1 complex competitively inhibits mRNA binding (to NUP98-RAE1), which is essential for its immune function. Likewise, overexpression of SARS-CoV-2: Nucleoprotein protein is observed to be associated with the attenuation of RIG-I-mediated interferon production via binding to TRIM25 and thus interrupting the interaction between TRIM25 and RIG-I (which is its natural protein partner) [<xref ref-type="bibr" rid="R116">116</xref>].</p><p id="P89">The SARS-CoV-2: human protein interactions associated with these 14 human proteins could be attractive targets for drug design that target the protein-protein interfaces. In particular, SARS-CoV-2: PLpro is known to be a promising target for designing protein-protein interaction inhibitors [<xref ref-type="bibr" rid="R118">118</xref>]. In our analyses, we modelled PLpro interactions with ISG15, IFIH1 and IFIT2. Interestingly, PLpro interactor protein IFIH1 is associated with drug-associated functional family in CATH. Likewise, we observed druggable CATH-FunFam for AXL and ARF6 proteins (interacting with Spike-NTD and NSP15 in SARS-CoV-2, respectively), where drugs have previously been identified that bind to structurally similar paralogs. The domain relatives within CATH-FunFams exhibit highly conserved drug binding sites and have the potential to be the druggable entities within drug targets, as shown in [<xref ref-type="bibr" rid="R60">60</xref>]. Thus, further studies targeting such immune proteins and PLpro-mediated interactions would be helpful.</p><p id="P90">We suggest monitoring both common and rare variants in human proteins, that are predicted to cause significant impact and thus likely to be associated with disease pathogenicity or susceptibility. Two affinity-enhancing variants – one from IFIH1 (Y13N) and one from ISG15 (S21N), are observed to occur at &gt; 1% allele frequency in East Asians and African population, respectively. Most of the variants identified in our study have allele frequencies (&lt;1%). A growing number of studies support the key role of rare variants in causing susceptibility/severity to COVID-19 [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R26">26</xref>–<xref ref-type="bibr" rid="R32">32</xref>].</p><p id="P91">We also provide a catalogue of protective variants from 14 proteins, particularly in ISG15 and TOMM70. These variants are observed to significantly reduce binding affinities of the human proteins to their SARS-CoV-2 partners. Earlier data showed a good correlation between predicted affinity-reducing variants and experimental observations [<xref ref-type="bibr" rid="R38">38</xref>]. Thus, affinity-reducing variants reported in this study could provide an explanation for why some individuals in specific populations are less likely to experience SARS-CoV-2 associated immune evasion.</p><p id="P92">Whilst we observed only two common variants in certain specific ethnic groups, occurrence of certain rare affinity-enhancing variants could also lead to increased susceptibility in individuals carrying them. Though the data suggest some role of genetic variation in COVID-19 susceptibility, the role of social and environmental factors should also be studied. In addition, our study is based on on computational prediction of changes in the binding affinity. Experimental data is available for variants in only a limited number of complexes such as spike-ACE2 and ORF9b-TOMM70. Future experimental studies would be helpful for proposed affinity-enhancing mutations in other immune proteins.</p></sec><sec id="S27" sec-type="conclusions"><title>Conclusions</title><p id="P93">We used structural bioinformatics approaches to predict human and viral protein variants affecting COVID-19 susceptibility and to suggest repurposing of therapeutics based on CATH functional family data associated with small molecules/drugs. A total of 26 affinity-enhancing variants are reported in our study and we discuss their structural impact in the context of functional sites using 3D structures of SARS-CoV-2: human complexes. The protocol designed in this study could be extended to analyse other protein interactions as more structures are experimentally determined and more powerful tools for protein structure prediction emerge. Our approach could be helpful in future studies of not only for COVID-19 but also other emerging infectious diseases.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary data</label><media xlink:href="EMS190885-supplement-Supplementary_data.zip" mimetype="application" mime-subtype="zip" id="d151aAdHbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S28"><title>Acknowledgements</title><p>David Gregory for setting up Colabfold at UCL cluster. Dr. Stuart MacGowan for his comments on the analyses. Molecular graphics and analyses performed with UCSF Chimera, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH P41-GM103311.</p><sec id="S29"><title>Funding</title><p>VPW acknowledges funding from UKRI BBSRC grant BB/W003368/1 ; PA: Wellcome Trust grant 221327/Z/20/Z. NB: Wellcome Trust grant 221327/Z/20/Z; NS - BB/S020144/1; LW - BB/M009513/1; S.D.L. is funded by a Fundamental Research Grant Scheme from the Ministry of Higher Education Malaysia [FRGS/1/2020/STG01/UKM/02/3]; Ian Sillitoe is funded by BBSRC [BB/R014892/1]; YG acknowledges funding from BBSRC [60175814].</p></sec></ack><sec id="S30" sec-type="data-availability"><title>Data availability</title><p id="P94">The data supporting the conclusions of the study is made available in the <xref ref-type="supplementary-material" rid="SD1">Supplementary files 1 to 8</xref>. The dataset of SARS-CoV-2:Human 3D-complexes used in this study is provided in <xref ref-type="supplementary-material" rid="SD1">Supplementary file 9</xref>.</p></sec><fn-group><fn fn-type="con" id="FN1"><p id="P95"><bold>Author Contributions</bold></p><p id="P96">CO: the conception of the work; VW,PA,NS,NB: data acquisition, VW,SD,NS, LW,YG,JW: analysis, VW,CO,PA,YG,LW, SD: interpretation of data; PA: designed FunVar pipeline used in the work. VW,CO,PA,YG,LW,VW,SD,IS: drafted the work. All authors have approved the submitted version. All authors have agreed to be accountable for their contributions in this work.</p></fn><fn fn-type="conflict" id="FN2"><p id="P97"><bold>Conflicts of interest</bold></p><p id="P98">Authors declare that there are no Conflicts of interest.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="book"><collab>W.H. Organization</collab><source>COVID-19 weekly epidemiological update, edition 150, 6 July 2023</source><year>2023</year></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergwerk</surname><given-names>M</given-names></name><etal/></person-group><article-title>Covid-19 breakthrough infections in vaccinated health care workers</article-title><source>New England Journal of Medicine</source><year>2021</year><volume>385</volume><issue>16</issue><fpage>1474</fpage><lpage>1484</lpage><pub-id pub-id-type="pmcid">PMC8362591</pub-id><pub-id pub-id-type="pmid">34320281</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2109072</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agyemang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Ethnic minority status as social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early phase of the pandemic: a meta-analysis</article-title><source>BMJ Glob Health</source><year>2021</year><volume>6</volume><issue>11</issue><pub-id pub-id-type="pmcid">PMC8573300</pub-id><pub-id pub-id-type="pmid">34740916</pub-id><pub-id pub-id-type="doi">10.1136/bmjgh-2021-007433</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>F</given-names></name><etal/></person-group><article-title>Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021</article-title><source>Eurosurveillance</source><year>2021</year><volume>26</volume><issue>24</issue><elocation-id>2100509</elocation-id><pub-id pub-id-type="pmcid">PMC8212592</pub-id><pub-id pub-id-type="pmid">34142653</pub-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2021.26.24.2100509</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coburn</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States</article-title><source>JAMA Netw Open</source><year>2022</year><volume>5</volume><issue>6</issue><elocation-id>e2215934</elocation-id><pub-id pub-id-type="pmcid">PMC9175076</pub-id><pub-id pub-id-type="pmid">35671054</pub-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.15934</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimball</surname><given-names>A</given-names></name><etal/></person-group><article-title>Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility—King County, Washington, March 2020</article-title><source>Morbidity and Mortality Weekly Report</source><year>2020</year><volume>69</volume><issue>13</issue><fpage>377</fpage><pub-id pub-id-type="pmcid">PMC7119514</pub-id><pub-id pub-id-type="pmid">32240128</pub-id><pub-id pub-id-type="doi">10.15585/mmwr.mm6913e1</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathur</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform</article-title><source>Lancet</source><year>2021</year><volume>397</volume><issue>10286</issue><fpage>1711</fpage><lpage>1724</lpage><pub-id pub-id-type="pmcid">PMC8087292</pub-id><pub-id pub-id-type="pmid">33939953</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00634-6</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiq</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Akram</surname><given-names>I</given-names></name></person-group><article-title>Clinical outcomes following COVID-19 infection in ethnic minority groups in the UK: a systematic review and meta-analysis</article-title><source>Public Health</source><year>2023</year><volume>222</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="pmcid">PMC9181265</pub-id><pub-id pub-id-type="pmid">35970621</pub-id><pub-id pub-id-type="doi">10.1016/j.puhe.2022.05.019</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>3528</fpage><pub-id pub-id-type="pmcid">PMC9240035</pub-id><pub-id pub-id-type="pmid">35764621</pub-id><pub-id pub-id-type="doi">10.1038/s41467-022-30836-0</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination</article-title><source>Biosaf Health</source><year>2022</year><volume>4</volume><issue>4</issue><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="pmcid">PMC9277989</pub-id><pub-id pub-id-type="pmid">35856045</pub-id><pub-id pub-id-type="doi">10.1016/j.bsheal.2022.07.001</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><article-title>Mapping the human genetic architecture of COVID-19</article-title><source>Nature</source><year>2021</year><volume>600</volume><issue>7889</issue><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="pmcid">PMC8674144</pub-id><pub-id pub-id-type="pmid">34237774</pub-id><pub-id pub-id-type="doi">10.1038/s41586-021-03767-x</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients</article-title><source>Genes Immun</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmcid">PMC8703210</pub-id><pub-id pub-id-type="pmid">34952932</pub-id><pub-id pub-id-type="doi">10.1038/s41435-021-00157-1</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemi</surname><given-names>MEK</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name></person-group><article-title>The human genetic epidemiology of COVID-19</article-title><source>Nat Rev Genet</source><year>2022</year><volume>23</volume><issue>9</issue><fpage>533</fpage><lpage>546</lpage><pub-id pub-id-type="pmcid">PMC9060414</pub-id><pub-id pub-id-type="pmid">35501396</pub-id><pub-id pub-id-type="doi">10.1038/s41576-022-00478-5</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms</article-title><source>Science</source><year>2020</year><volume>370</volume><issue>6521</issue><pub-id pub-id-type="pmcid">PMC7808408</pub-id><pub-id pub-id-type="pmid">33060197</pub-id><pub-id pub-id-type="doi">10.1126/science.abe9403</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>DE</given-names></name><etal/></person-group><article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title><source>Nature</source><year>2020</year><volume>583</volume><issue>7816</issue><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="pmcid">PMC7431030</pub-id><pub-id pub-id-type="pmid">32353859</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>SARS-CoV-2-host proteome interactions for antiviral drug discovery</article-title><source>Mol Syst Biol</source><year>2021</year><volume>17</volume><issue>11</issue><elocation-id>e10396</elocation-id><pub-id pub-id-type="pmcid">PMC8552907</pub-id><pub-id pub-id-type="pmid">34709727</pub-id><pub-id pub-id-type="doi">10.15252/msb.202110396</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabeel-Shah</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress granules to impair host stress response</article-title><source>iScience</source><year>2022</year><volume>25</volume><issue>1</issue><elocation-id>103562</elocation-id><pub-id pub-id-type="pmcid">PMC8642831</pub-id><pub-id pub-id-type="pmid">34901782</pub-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.103562</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stukalov</surname><given-names>A</given-names></name><etal/></person-group><article-title>Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV</article-title><source>Nature</source><year>2021</year><volume>594</volume><issue>7862</issue><fpage>246</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">33845483</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DK</given-names></name><etal/></person-group><article-title>A proteome-scale map of the SARS-CoV-2-human contactome</article-title><source>Nat Biotechnol</source><year>2023</year><volume>41</volume><issue>1</issue><fpage>140</fpage><lpage>149</lpage><pub-id pub-id-type="pmcid">PMC9849141</pub-id><pub-id pub-id-type="pmid">36217029</pub-id><pub-id pub-id-type="doi">10.1038/s41587-022-01475-z</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Toro</surname><given-names>N</given-names></name><etal/></person-group><article-title>The IntAct database: efficient access to fine-grained molecular interaction data</article-title><source>Nucleic Acids Res</source><year>2022</year><volume>50</volume><issue>D1</issue><fpage>D648</fpage><lpage>d653</lpage><pub-id pub-id-type="pmcid">PMC8728211</pub-id><pub-id pub-id-type="pmid">34761267</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkab1006</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oughtred</surname><given-names>R</given-names></name><etal/></person-group><article-title>The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions</article-title><source>Protein Sci</source><year>2021</year><volume>30</volume><issue>1</issue><fpage>187</fpage><lpage>200</lpage><pub-id pub-id-type="pmcid">PMC7737760</pub-id><pub-id pub-id-type="pmid">33070389</pub-id><pub-id pub-id-type="doi">10.1002/pro.3978</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrin-Cocon</surname><given-names>L</given-names></name><etal/></person-group><article-title>The current landscape of coronavirus-host protein-protein interactions</article-title><source>J Transl Med</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>319</fpage><pub-id pub-id-type="pmcid">PMC7432461</pub-id><pub-id pub-id-type="pmid">32811513</pub-id><pub-id pub-id-type="doi">10.1186/s12967-020-02480-z</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Interferon resistance of emerging SARS-CoV-2 variants</article-title><source>Proc Natl Acad Sci U S A</source><year>2022</year><volume>119</volume><issue>32</issue><elocation-id>e2203760119</elocation-id><pub-id pub-id-type="pmcid">PMC9371743</pub-id><pub-id pub-id-type="pmid">35867811</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2203760119</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H</given-names></name><etal/></person-group><article-title>Evasion of Type I Interferon by SARS-CoV-2</article-title><source>Cell Rep</source><year>2020</year><volume>33</volume><issue>1</issue><elocation-id>108234</elocation-id><pub-id pub-id-type="pmcid">PMC7501843</pub-id><pub-id pub-id-type="pmid">32979938</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108234</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>PE</given-names></name><name><surname>Bartlett</surname><given-names>AW</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name></person-group><article-title>Severe COVID-19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals</article-title><source>Clin Transl Immunology</source><year>2022</year><volume>11</volume><issue>4</issue><elocation-id>e1365</elocation-id><pub-id pub-id-type="pmcid">PMC9013505</pub-id><pub-id pub-id-type="pmid">35444807</pub-id><pub-id pub-id-type="doi">10.1002/cti2.1365</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Rare Variants in Inborn Errors of Immunity Genes Associated With Covid-19 Severity</article-title><source>Front Cell Infect Microbiol</source><year>2022</year><volume>12</volume><elocation-id>888582</elocation-id><pub-id pub-id-type="pmcid">PMC9184678</pub-id><pub-id pub-id-type="pmid">35694544</pub-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.888582</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallerini</surname><given-names>C</given-names></name><etal/></person-group><article-title>Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity</article-title><source>Hum Genet</source><year>2022</year><volume>141</volume><issue>1</issue><fpage>147</fpage><lpage>173</lpage><pub-id pub-id-type="pmcid">PMC8661833</pub-id><pub-id pub-id-type="pmid">34889978</pub-id><pub-id pub-id-type="doi">10.1007/s00439-021-02397-7</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergantini</surname><given-names>L</given-names></name><etal/></person-group><article-title>Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder</article-title><source>Respir Res</source><year>2023</year><volume>24</volume><issue>1</issue><fpage>158</fpage><pub-id pub-id-type="pmcid">PMC10276396</pub-id><pub-id pub-id-type="pmid">37328761</pub-id><pub-id pub-id-type="doi">10.1186/s12931-023-02458-7</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler-Laporte</surname><given-names>G</given-names></name><etal/></person-group><article-title>Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative</article-title><source>PLoS Genet</source><year>2022</year><volume>18</volume><issue>11</issue><elocation-id>e1010367</elocation-id><pub-id pub-id-type="pmcid">PMC9632827</pub-id><pub-id pub-id-type="pmid">36327219</pub-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1010367</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khadzhieva</surname><given-names>MB</given-names></name><etal/></person-group><article-title>COVID-19 severity: does the genetic landscape of rare variants matter?</article-title><source>Front Genet</source><year>2023</year><volume>14</volume><elocation-id>1152768</elocation-id><pub-id pub-id-type="pmcid">PMC10339319</pub-id><pub-id pub-id-type="pmid">37456666</pub-id><pub-id pub-id-type="doi">10.3389/fgene.2023.1152768</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matuozzo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19</article-title><source>medRxiv</source><year>2022</year><pub-id pub-id-type="pmcid">PMC10074346</pub-id><pub-id pub-id-type="pmid">37020259</pub-id><pub-id pub-id-type="doi">10.1186/s13073-023-01173-8</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zguro</surname><given-names>K</given-names></name><etal/></person-group><article-title>Host genetic basis of COVID-19: from methodologies to genes</article-title><source>Eur J Hum Genet</source><year>2022</year><volume>30</volume><issue>8</issue><fpage>899</fpage><lpage>907</lpage><pub-id pub-id-type="pmcid">PMC9135575</pub-id><pub-id pub-id-type="pmid">35618891</pub-id><pub-id pub-id-type="doi">10.1038/s41431-022-01121-x</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorne</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Evolution of enhanced innate immune evasion by SARS-CoV-2</article-title><source>Nature</source><year>2022</year><volume>602</volume><issue>7897</issue><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="pmcid">PMC8850198</pub-id><pub-id pub-id-type="pmid">34942634</pub-id><pub-id pub-id-type="doi">10.1038/s41586-021-04352-y</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minkoff</surname><given-names>JM</given-names></name><name><surname>tenOever</surname><given-names>B</given-names></name></person-group><article-title>Innate immune evasion strategies of SARS-CoV-2</article-title><source>Nat Rev Microbiol</source><year>2023</year><volume>21</volume><issue>3</issue><fpage>178</fpage><lpage>194</lpage><pub-id pub-id-type="pmcid">PMC9838430</pub-id><pub-id pub-id-type="pmid">36631691</pub-id><pub-id pub-id-type="doi">10.1038/s41579-022-00839-1</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>K</given-names></name><etal/></person-group><article-title>Overexpression of SARS-CoV-2 protein ORF6 dislocates RAE1 and NUP98 from the nuclear pore complex</article-title><source>Biochem Biophys Res Commun</source><year>2021</year><volume>536</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="pmcid">PMC7733692</pub-id><pub-id pub-id-type="pmid">33360543</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.11.115</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><article-title>Innate immunity:the first line of defense against SARS-CoV-2</article-title><source>Nat Immunol</source><year>2022</year><volume>23</volume><issue>2</issue><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="pmcid">PMC8935980</pub-id><pub-id pub-id-type="pmid">35105981</pub-id><pub-id pub-id-type="doi">10.1038/s41590-021-01091-0</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics</article-title><source>Elife</source><year>2021</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC8480977</pub-id><pub-id pub-id-type="pmid">34435953</pub-id><pub-id pub-id-type="doi">10.7554/eLife.70658</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacGowan</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Missense variants in human ACE2 strongly affect binding to SARS-CoV-2 Spike providing a mechanism for ACE2 mediated genetic risk in Covid-19: A case study in affinity predictions of interface variants</article-title><source>PLoS Comput Biol</source><year>2022</year><volume>18</volume><issue>3</issue><elocation-id>e1009922</elocation-id><pub-id pub-id-type="pmcid">PMC8920257</pub-id><pub-id pub-id-type="pmid">35235558</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1009922</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelli</surname><given-names>S</given-names></name><etal/></person-group><article-title>Author Correction: Exploring the structural distribution of genetic variation in SARS-CoV-2 with the COVID-3D online resource</article-title><source>Nat Genet</source><year>2021</year><volume>53</volume><issue>2</issue><fpage>254</fpage><pub-id pub-id-type="pmcid">PMC7781176</pub-id><pub-id pub-id-type="pmid">33398199</pub-id><pub-id pub-id-type="doi">10.1038/s41588-020-00775-x</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suryamohan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2</article-title><source>Commun Biol</source><year>2021</year><volume>4</volume><issue>1</issue><fpage>475</fpage><pub-id pub-id-type="pmcid">PMC8041869</pub-id><pub-id pub-id-type="pmid">33846513</pub-id><pub-id pub-id-type="doi">10.1038/s42003-021-02030-3</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsulami</surname><given-names>AF</given-names></name><etal/></person-group><article-title>SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets</article-title><source>Brief Bioinform</source><year>2021</year><volume>22</volume><issue>2</issue><fpage>769</fpage><lpage>780</lpage><pub-id pub-id-type="pmcid">PMC7929435</pub-id><pub-id pub-id-type="pmid">33416848</pub-id><pub-id pub-id-type="doi">10.1093/bib/bbaa404</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wierbowski</surname><given-names>SD</given-names></name><etal/></person-group><article-title>A 3D structural SARS-CoV-2-human interactome to explore genetic and drug perturbations</article-title><source>Nat Methods</source><year>2021</year><volume>18</volume><issue>12</issue><fpage>1477</fpage><lpage>1488</lpage><pub-id pub-id-type="pmcid">PMC8665054</pub-id><pub-id pub-id-type="pmid">34845387</pub-id><pub-id pub-id-type="doi">10.1038/s41592-021-01318-w</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunham</surname><given-names>Aea</given-names></name></person-group><article-title>A missense variant effect prediction and annotation resource for SARS-CoV-2</article-title><source>BioRxiv</source></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R</surname><given-names>E</given-names></name><etal/></person-group><article-title>Protein complex prediction with AlphaFold-Multimer</article-title><source>BiorXiv</source><year>2022</year></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lensink</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of AlphaFold on Structure Prediction of Protein Complexes: The CASP15-CAPRI Experiment</article-title><year>2023</year><pub-id pub-id-type="pmid">37905971</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><article-title>Protein structure predictions to atomic accuracy with AlphaFold</article-title><source>Nat Methods</source><year>2022</year><volume>19</volume><issue>1</issue><fpage>11</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">35017726</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>P</given-names></name><name><surname>Pozzati</surname><given-names>G</given-names></name><name><surname>Elofsson</surname><given-names>A</given-names></name></person-group><article-title>Improved prediction of protein-protein interactions using AlphaFold2</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>1265</fpage><pub-id pub-id-type="pmcid">PMC8913741</pub-id><pub-id pub-id-type="pmid">35273146</pub-id><pub-id pub-id-type="doi">10.1038/s41467-022-28865-w</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>R</given-names></name><etal/></person-group><article-title>Benchmarking AlphaFold for protein complex modeling reveals accuracy determinants</article-title><source>Protein Sci</source><year>2022</year><volume>31</volume><issue>8</issue><elocation-id>e4379</elocation-id><pub-id pub-id-type="pmcid">PMC9278006</pub-id><pub-id pub-id-type="pmid">35900023</pub-id><pub-id pub-id-type="doi">10.1002/pro.4379</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>HM</given-names></name><etal/></person-group><article-title>The Protein Data Bank</article-title><source>Nucleic Acids Res</source><year>2000</year><volume>28</volume><issue>1</issue><fpage>235</fpage><lpage>42</lpage><pub-id pub-id-type="pmcid">PMC102472</pub-id><pub-id pub-id-type="pmid">10592235</pub-id><pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title><source>Nature</source><year>2020</year><volume>581</volume><issue>7809</issue><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="pmcid">PMC7334197</pub-id><pub-id pub-id-type="pmid">32461654</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><article-title>The GenomeAsia 100K Project enables genetic discoveries across Asia</article-title><source>Nature</source><year>2019</year><volume>576</volume><issue>7785</issue><fpage>106</fpage><lpage>111</lpage><pub-id pub-id-type="pmcid">PMC7054211</pub-id><pub-id pub-id-type="pmid">31802016</pub-id><pub-id pub-id-type="doi">10.1038/s41586-019-1793-z</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><article-title>An integrated national scale SARS-CoV-2 genomic surveillance network</article-title><source>Lancet Microbe</source><year>2020</year><volume>1</volume><issue>3</issue><fpage>e99</fpage><lpage>e100</lpage><pub-id pub-id-type="pmcid">PMC7266609</pub-id><pub-id pub-id-type="pmid">32835336</pub-id><pub-id pub-id-type="doi">10.1016/S2666-5247(20)30054-9</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>JG</given-names></name><name><surname>Cotten</surname><given-names>M</given-names></name><name><surname>Robertson</surname><given-names>D</given-names></name></person-group><article-title>CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation</article-title><source>Preprints</source><year>2020</year></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulo</surname><given-names>C</given-names></name><etal/></person-group><article-title>ViralZone: a knowledge resource to understand virus diversity</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>Database issue</issue><fpage>D576</fpage><lpage>82</lpage><pub-id pub-id-type="pmcid">PMC3013774</pub-id><pub-id pub-id-type="pmid">20947564</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkq901</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>CHM</given-names></name><etal/></person-group><article-title>mCSM-PPI2: predicting the effects of mutations on protein-protein interactions</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>W1</issue><fpage>W338</fpage><lpage>w344</lpage><pub-id pub-id-type="pmcid">PMC6602427</pub-id><pub-id pub-id-type="pmid">31114883</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkz383</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><etal/></person-group><article-title>Functional classification of CATH superfamilies: a domain-based approach for protein function annotation</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><issue>21</issue><fpage>3460</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC4612221</pub-id><pub-id pub-id-type="pmid">26139634</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btv398</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><etal/></person-group><article-title>CATH FunFHMMer web server: protein functional annotations using functional family assignments</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><issue>W1</issue><fpage>W148</fpage><lpage>53</lpage><pub-id pub-id-type="pmcid">PMC4489299</pub-id><pub-id pub-id-type="pmid">25964299</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkv488</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>N</given-names></name><etal/></person-group><article-title>The CAFA challenge reports improved protein function prediction and new functional annotations for hundreds of genes through experimental screens</article-title><source>Genome Biol</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>244</fpage><pub-id pub-id-type="pmcid">PMC6864930</pub-id><pub-id pub-id-type="pmid">31744546</pub-id><pub-id pub-id-type="doi">10.1186/s13059-019-1835-8</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaulton</surname><given-names>A</given-names></name><etal/></person-group><article-title>ChEMBL: a large-scale bioactivity database for drug discovery</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><issue>Database issue</issue><fpage>D1100</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC3245175</pub-id><pub-id pub-id-type="pmid">21948594</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkr777</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moya-García</surname><given-names>A</given-names></name><etal/></person-group><article-title>Structural and Functional View of Polypharmacology</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><elocation-id>10102</elocation-id><pub-id pub-id-type="pmcid">PMC5579063</pub-id><pub-id pub-id-type="pmid">28860623</pub-id><pub-id pub-id-type="doi">10.1038/s41598-017-10012-x</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apweiler</surname><given-names>R</given-names></name><etal/></person-group><article-title>UniProt: the Universal Protein knowledgebase</article-title><source>Nucleic Acids Res</source><year>2004</year><volume>32</volume><issue>Database issue</issue><fpage>D115</fpage><lpage>9</lpage><pub-id pub-id-type="pmcid">PMC308865</pub-id><pub-id pub-id-type="pmid">14681372</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkh131</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villaveces</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Merging and scoring molecular interactions utilising existing community standards: tools, use-cases and a case study</article-title><source>Database (Oxford)</source><year>2015</year><volume>2015</volume><pub-id pub-id-type="pmcid">PMC4316181</pub-id><pub-id pub-id-type="pmid">25652942</pub-id><pub-id pub-id-type="doi">10.1093/database/bau131</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleksander</surname><given-names>SA</given-names></name><etal/></person-group><article-title>The Gene Ontology knowledgebase in 2023</article-title><source>Genetics</source><year>2023</year><volume>224</volume><issue>1</issue><pub-id pub-id-type="pmcid">PMC10158837</pub-id><pub-id pub-id-type="pmid">36866529</pub-id><pub-id pub-id-type="doi">10.1093/genetics/iyad031</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breuer</surname><given-names>K</given-names></name><etal/></person-group><article-title>InnateDB: systems biology of innate immunity and beyond--recent updates and continuing curation</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><issue>Database issue</issue><fpage>D1228</fpage><lpage>33</lpage><pub-id pub-id-type="pmcid">PMC3531080</pub-id><pub-id pub-id-type="pmid">23180781</pub-id><pub-id pub-id-type="doi">10.1093/nar/gks1147</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orengo</surname><given-names>CA</given-names></name><etal/></person-group><article-title>CATH--a hierarchic classification of protein domain structures</article-title><source>Structure</source><year>1997</year><volume>5</volume><issue>8</issue><fpage>1093</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">9309224</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sillitoe</surname><given-names>I</given-names></name><etal/></person-group><article-title>CATH: increased structural coverage of functional space</article-title><source>Nucleic Acids Res</source><year>2021</year><volume>49</volume><issue>D1</issue><fpage>D266</fpage><lpage>d273</lpage><pub-id pub-id-type="pmcid">PMC7778904</pub-id><pub-id pub-id-type="pmid">33237325</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkaa1079</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potter</surname><given-names>SC</given-names></name><etal/></person-group><article-title>HMMER web server: 2018 update</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><issue>W1</issue><fpage>W200</fpage><lpage>w204</lpage><pub-id pub-id-type="pmcid">PMC6030962</pub-id><pub-id pub-id-type="pmid">29905871</pub-id><pub-id pub-id-type="doi">10.1093/nar/gky448</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>TE</given-names></name><name><surname>Sillitoe</surname><given-names>I</given-names></name><name><surname>Lees</surname><given-names>JG</given-names></name></person-group><article-title>cath-resolve-hits: a new tool that resolves domain matches suspiciously quickly</article-title><source>Bioinformatics</source><year>2019</year><volume>35</volume><issue>10</issue><fpage>1766</fpage><lpage>1767</lpage><pub-id pub-id-type="pmcid">PMC6513158</pub-id><pub-id pub-id-type="pmid">30295745</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bty863</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdar</surname><given-names>WS</given-names></name></person-group><article-title>Scoring residue conservation</article-title><source>Proteins</source><year>2002</year><volume>48</volume><issue>2</issue><fpage>227</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">12112692</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laskowski</surname><given-names>RA</given-names></name><etal/></person-group><article-title>VarSite: Disease variants and protein structure</article-title><source>Protein Sci</source><year>2020</year><volume>29</volume><issue>1</issue><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="pmcid">PMC6933866</pub-id><pub-id pub-id-type="pmid">31606900</pub-id><pub-id pub-id-type="doi">10.1002/pro.3746</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>BioLiP: a semi-manually curated database for biologically relevant ligand-protein interactions</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><issue>Database issue</issue><fpage>D1096</fpage><lpage>103</lpage><pub-id pub-id-type="pmcid">PMC3531193</pub-id><pub-id pub-id-type="pmid">23087378</pub-id><pub-id pub-id-type="doi">10.1093/nar/gks966</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laskowski</surname><given-names>RA</given-names></name><etal/></person-group><article-title>PDBsum: Structural summaries of PDB entries</article-title><source>Protein Sci</source><year>2018</year><volume>27</volume><issue>1</issue><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="pmcid">PMC5734310</pub-id><pub-id pub-id-type="pmid">28875543</pub-id><pub-id pub-id-type="doi">10.1002/pro.3289</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>AJM</given-names></name><etal/></person-group><article-title>Mechanism and Catalytic Site Atlas (M-CSA): a database of enzyme reaction mechanisms and active sites</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><issue>D1</issue><fpage>D618</fpage><lpage>d623</lpage><pub-id pub-id-type="pmcid">PMC5753290</pub-id><pub-id pub-id-type="pmid">29106569</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkx1012</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephenson</surname><given-names>JD</given-names></name><etal/></person-group><article-title>VarMap: a web tool for mapping genomic coordinates to protein sequence and structure and retrieving protein structural annotations</article-title><source>Bioinformatics</source><year>2019</year><volume>35</volume><issue>22</issue><fpage>4854</fpage><lpage>4856</lpage><pub-id pub-id-type="pmcid">PMC6853667</pub-id><pub-id pub-id-type="pmid">31192369</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btz482</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rentzsch</surname><given-names>P</given-names></name><etal/></person-group><article-title>CADD: predicting the deleteriousness of variants throughout the human genome</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>D1</issue><fpage>D886</fpage><lpage>d894</lpage><pub-id pub-id-type="pmcid">PMC6323892</pub-id><pub-id pub-id-type="pmid">30371827</pub-id><pub-id pub-id-type="doi">10.1093/nar/gky1016</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>PC</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name></person-group><article-title>SIFT: Predicting amino acid changes that affect protein function</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><issue>13</issue><fpage>3812</fpage><lpage>4</lpage><pub-id pub-id-type="pmcid">PMC168916</pub-id><pub-id pub-id-type="pmid">12824425</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkg509</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirdita</surname><given-names>M</given-names></name><etal/></person-group><article-title>ColabFold: making protein folding accessible to all</article-title><source>Nat Methods</source><year>2022</year><volume>19</volume><issue>6</issue><fpage>679</fpage><lpage>682</lpage><pub-id pub-id-type="pmcid">PMC9184281</pub-id><pub-id pub-id-type="pmid">35637307</pub-id><pub-id pub-id-type="doi">10.1038/s41592-022-01488-1</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Protein Interaction Z Score Assessment (PIZSA): an empirical scoring scheme for evaluation of protein-protein interactions</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>W1</issue><fpage>W331</fpage><lpage>w337</lpage><pub-id pub-id-type="pmcid">PMC6602501</pub-id><pub-id pub-id-type="pmid">31114890</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkz368</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vangone</surname><given-names>A</given-names></name><name><surname>Bonvin</surname><given-names>A</given-names></name></person-group><article-title>PRODIGY: A Contact-based Predictor of Binding Affinity in Protein-protein Complexes</article-title><source>Bio Protoc</source><year>2017</year><volume>7</volume><issue>3</issue><elocation-id>e2124</elocation-id><pub-id pub-id-type="pmcid">PMC8376549</pub-id><pub-id pub-id-type="pmid">34458447</pub-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2124</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><etal/></person-group><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>J Comput Chem</source><year>2004</year><volume>25</volume><issue>13</issue><fpage>1605</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Computational prediction of protein interfaces: A review of data driven methods</article-title><source>FEBS Lett</source><year>2015</year><volume>589</volume><issue>23</issue><fpage>3516</fpage><lpage>26</lpage><pub-id pub-id-type="pmcid">PMC4655202</pub-id><pub-id pub-id-type="pmid">26460190</pub-id><pub-id pub-id-type="doi">10.1016/j.febslet.2015.10.003</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>SD</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><elocation-id>16471</elocation-id><pub-id pub-id-type="pmcid">PMC7536205</pub-id><pub-id pub-id-type="pmid">33020502</pub-id><pub-id pub-id-type="doi">10.1038/s41598-020-71936-5</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>A</given-names></name><etal/></person-group><article-title>IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes</article-title><source>Nucleic Acids Res</source><year>2021</year><volume>49</volume><issue>D1</issue><fpage>D1225</fpage><lpage>d1232</lpage><pub-id pub-id-type="pmcid">PMC7778947</pub-id><pub-id pub-id-type="pmid">33095885</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkaa923</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ameur</surname><given-names>A</given-names></name><etal/></person-group><article-title>SweGen: a whole-genome data resource of genetic variability in a cross-section of the Swedish population</article-title><source>Eur J Hum Genet</source><year>2017</year><volume>25</volume><issue>11</issue><fpage>1253</fpage><lpage>1260</lpage><pub-id pub-id-type="pmcid">PMC5765326</pub-id><pub-id pub-id-type="pmid">28832569</pub-id><pub-id pub-id-type="doi">10.1038/ejhg.2017.130</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadaka</surname><given-names>S</given-names></name><etal/></person-group><article-title>jMorp: Japanese Multi Omics Reference Panel</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><issue>D1</issue><fpage>D551</fpage><lpage>d557</lpage><pub-id pub-id-type="pmcid">PMC5753289</pub-id><pub-id pub-id-type="pmid">29069501</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkx978</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>AH</given-names></name><etal/></person-group><article-title>The All of Us Research Program: Data quality, utility, and diversity</article-title><source>Patterns (N Y)</source><year>2022</year><volume>3</volume><issue>8</issue><elocation-id>100570</elocation-id><pub-id pub-id-type="pmcid">PMC9403360</pub-id><pub-id pub-id-type="pmid">36033590</pub-id><pub-id pub-id-type="doi">10.1016/j.patter.2022.100570</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pejaver</surname><given-names>V</given-names></name><etal/></person-group><article-title>Inferring the molecular and phenotypic impact of amino acid variants with MutPred2</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>5918</fpage><pub-id pub-id-type="pmcid">PMC7680112</pub-id><pub-id pub-id-type="pmid">33219223</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-19669-x</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamburov</surname><given-names>A</given-names></name><etal/></person-group><article-title>ConsensusPathDB--a database for integrating human functional interaction networks</article-title><source>Nucleic Acids Res</source><year>2009</year><volume>37</volume><issue>Database issue</issue><fpage>D623</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC2686562</pub-id><pub-id pub-id-type="pmid">18940869</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkn698</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><etal/></person-group><article-title>The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest</article-title><source>Nucleic Acids Res</source><year>2023</year><volume>51</volume><issue>D1</issue><fpage>D638</fpage><lpage>d646</lpage><pub-id pub-id-type="pmcid">PMC9825434</pub-id><pub-id pub-id-type="pmid">36370105</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkac1000</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomasoni</surname><given-names>M</given-names></name><etal/></person-group><article-title>MONET: a toolbox integrating top-performing methods for network modularization</article-title><source>Bioinformatics</source><year>2020</year><volume>36</volume><issue>12</issue><fpage>3920</fpage><lpage>3921</lpage><pub-id pub-id-type="pmcid">PMC7320625</pub-id><pub-id pub-id-type="pmid">32271874</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa236</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raudvere</surname><given-names>U</given-names></name><etal/></person-group><article-title>g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>W1</issue><fpage>W191</fpage><lpage>w198</lpage><pub-id pub-id-type="pmcid">PMC6602461</pub-id><pub-id pub-id-type="pmid">31066453</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkz369</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi-Tope</surname><given-names>G</given-names></name><etal/></person-group><article-title>Reactome: a knowledgebase of biological pathways</article-title><source>Nucleic Acids Res</source><year>2005</year><volume>33</volume><issue>Database issue</issue><fpage>D428</fpage><lpage>32</lpage><pub-id pub-id-type="pmcid">PMC540026</pub-id><pub-id pub-id-type="pmid">15608231</pub-id><pub-id pub-id-type="doi">10.1093/nar/gki072</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>H</given-names></name><etal/></person-group><article-title>KEGG: Kyoto Encyclopedia of Genes and Genomes</article-title><source>Nucleic Acids Res</source><year>1999</year><volume>27</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="pmcid">PMC148090</pub-id><pub-id pub-id-type="pmid">9847135</pub-id><pub-id pub-id-type="doi">10.1093/nar/27.1.29</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Ensembl 2023</article-title><source>Nucleic Acids Res</source><year>2023</year><volume>51</volume><issue>D1</issue><fpage>D933</fpage><lpage>d941</lpage><pub-id pub-id-type="pmcid">PMC9825606</pub-id><pub-id pub-id-type="pmid">36318249</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkac958</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>CavityPlus 2022 Update: An Integrated Platform for Comprehensive Protein Cavity Detection and Property Analyses with User-friendly Tools and Cavity Databases</article-title><source>J Mol Biol</source><year>2023</year><volume>435</volume><issue>14</issue><elocation-id>168141</elocation-id><pub-id pub-id-type="pmid">37356903</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Rosa</surname><given-names>RL</given-names></name><etal/></person-group><article-title>SARSCOVIDB-A New Platform for the Analysis of the Molecular Impact of SARS-CoV-2 Viral Infection</article-title><source>ACS Omega</source><year>2021</year><volume>6</volume><issue>4</issue><fpage>3238</fpage><lpage>3243</lpage><pub-id pub-id-type="pmcid">PMC7839156</pub-id><pub-id pub-id-type="pmid">33553941</pub-id><pub-id pub-id-type="doi">10.1021/acsomega.0c05701</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>HW</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70</article-title><source>Cell Mol Immunol</source><year>2020</year><volume>17</volume><issue>9</issue><fpage>998</fpage><lpage>1000</lpage><pub-id pub-id-type="pmcid">PMC7387808</pub-id><pub-id pub-id-type="pmid">32728199</pub-id><pub-id pub-id-type="doi">10.1038/s41423-020-0514-8</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus-host interactions</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>2843</fpage><pub-id pub-id-type="pmcid">PMC8121815</pub-id><pub-id pub-id-type="pmid">33990585</pub-id><pub-id pub-id-type="doi">10.1038/s41467-021-23118-8</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandherm</surname><given-names>L</given-names></name><etal/></person-group><article-title>Phosphorylation of SARS-CoV-2 Orf9b Regulates Its Targeting to Two Binding Sites in TOM70 and Recruitment of Hsp90</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>17</issue><pub-id pub-id-type="pmcid">PMC8430508</pub-id><pub-id pub-id-type="pmid">34502139</pub-id><pub-id pub-id-type="doi">10.3390/ijms22179233</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity</article-title><source>Nature</source><year>2020</year><volume>587</volume><issue>7835</issue><fpage>657</fpage><lpage>662</lpage><pub-id pub-id-type="pmcid">PMC7116779</pub-id><pub-id pub-id-type="pmid">32726803</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2601-5</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies</article-title><source>PLoS One</source><year>2021</year><volume>16</volume><issue>7</issue><elocation-id>e0253364</elocation-id><pub-id pub-id-type="pmcid">PMC8284666</pub-id><pub-id pub-id-type="pmid">34270554</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0253364</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoudvand</surname><given-names>S</given-names></name><name><surname>Shokri</surname><given-names>S</given-names></name></person-group><article-title>Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19</article-title><source>Scand J Immunol</source><year>2021</year><volume>94</volume><issue>4</issue><elocation-id>e13044</elocation-id><pub-id pub-id-type="pmcid">PMC8250271</pub-id><pub-id pub-id-type="pmid">33872387</pub-id><pub-id pub-id-type="doi">10.1111/sji.13044</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>AG</given-names><suffix>Junior</suffix></name><name><surname>Sampaio</surname><given-names>NG</given-names></name><name><surname>Rehwinkel</surname><given-names>J</given-names></name></person-group><article-title>A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation</article-title><source>Trends Microbiol</source><year>2019</year><volume>27</volume><issue>1</issue><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="pmcid">PMC6319154</pub-id><pub-id pub-id-type="pmid">30201512</pub-id><pub-id pub-id-type="doi">10.1016/j.tim.2018.08.007</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><etal/></person-group><article-title>ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity</article-title><source>Nat Microbiol</source><year>2021</year><volume>6</volume><issue>4</issue><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="pmcid">PMC8103894</pub-id><pub-id pub-id-type="pmid">33727702</pub-id><pub-id pub-id-type="doi">10.1038/s41564-021-00884-1</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>How SARS-CoV-2 dodges immune surveillance and facilitates infection: an analytical review</article-title><source>Expert Rev Anti Infect Ther</source><year>2022</year><volume>20</volume><issue>8</issue><fpage>1119</fpage><lpage>1127</lpage><pub-id pub-id-type="pmid">35574688</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wydorski</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin</article-title><source>bioRxiv</source><year>2023</year><pub-id pub-id-type="pmcid">PMC10126577</pub-id><pub-id pub-id-type="pmid">37185902</pub-id><pub-id pub-id-type="doi">10.1038/s41467-023-38031-5</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Coronaviral PLpro proteases and the immunomodulatory roles of conjugated versus free Interferon Stimulated Gene product-15 (ISG15)</article-title><source>Semin Cell Dev Biol</source><year>2022</year><volume>132</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="pmcid">PMC9233553</pub-id><pub-id pub-id-type="pmid">35764457</pub-id><pub-id pub-id-type="doi">10.1016/j.semcdb.2022.06.005</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mapping allosteric communications within individual proteins</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><elocation-id>3862</elocation-id><pub-id pub-id-type="pmcid">PMC7395124</pub-id><pub-id pub-id-type="pmid">32737291</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-17618-2</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landrum</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>ClinVar: improving access to variant interpretations and supporting evidence</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><issue>D1</issue><fpage>D1062</fpage><lpage>d1067</lpage><pub-id pub-id-type="pmcid">PMC5753237</pub-id><pub-id pub-id-type="pmid">29165669</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkx1153</pub-id></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogunovic</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency</article-title><source>Science</source><year>2012</year><volume>337</volume><issue>6102</issue><fpage>1684</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC3507439</pub-id><pub-id pub-id-type="pmid">22859821</pub-id><pub-id pub-id-type="doi">10.1126/science.1224026</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation</article-title><source>Nature</source><year>2015</year><volume>517</volume><issue>7532</issue><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="pmcid">PMC4303590</pub-id><pub-id pub-id-type="pmid">25307056</pub-id><pub-id pub-id-type="doi">10.1038/nature13801</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penninck</surname><given-names>DG</given-names></name><name><surname>Feldman</surname><given-names>EC</given-names></name><name><surname>Nyland</surname><given-names>TG</given-names></name></person-group><article-title>Radiographic features of canine hyperadrenocorticism caused by autonomously functioning adrenocortical tumors: 23 cases (1978-1986)</article-title><source>J Am Vet Med Assoc</source><year>1988</year><volume>192</volume><issue>11</issue><fpage>1604</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3410782</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XY</given-names></name><etal/></person-group><article-title>Tom70 mediates activation of interferon regulatory factor 3 on mitochondria</article-title><source>Cell Res</source><year>2010</year><volume>20</volume><issue>9</issue><fpage>994</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">20628368</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirabelli</surname><given-names>C</given-names></name><etal/></person-group><article-title>ARF6 is a host factor for SARS-CoV-2 infection in vitro</article-title><source>bioRxiv</source><year>2022</year><pub-id pub-id-type="pmcid">PMC10397720</pub-id><pub-id pub-id-type="pmid">37342971</pub-id><pub-id pub-id-type="doi">10.1099/jgv.0.001868</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodsell</surname><given-names>DS</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><article-title>Automated docking of substrates to proteins by simulated annealing</article-title><source>Proteins</source><year>1990</year><volume>8</volume><issue>3</issue><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">2281083</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gori Savellini</surname><given-names>G</given-names></name><etal/></person-group><article-title>SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity</article-title><source>Viruses</source><year>2021</year><volume>13</volume><issue>8</issue><pub-id pub-id-type="pmcid">PMC8402637</pub-id><pub-id pub-id-type="pmid">34452305</pub-id><pub-id pub-id-type="doi">10.3390/v13081439</pub-id></element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><article-title>Molecular Mechanism of SARS-CoVs Orf6 Targeting the Rae1-Nup98 Complex to Compete With mRNA Nuclear Export</article-title><source>Front Mol Biosci</source><year>2021</year><volume>8</volume><elocation-id>813248</elocation-id><pub-id pub-id-type="pmcid">PMC8790125</pub-id><pub-id pub-id-type="pmid">35096974</pub-id><pub-id pub-id-type="doi">10.3389/fmolb.2021.813248</pub-id></element-citation></ref><ref id="R118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>488</fpage><pub-id pub-id-type="pmcid">PMC7817691</pub-id><pub-id pub-id-type="pmid">33473130</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-20718-8</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Flow-chart of the methodology used in this study.</title><p>The dataset of SARS-CoV-2: human protein interactors is analysed using variants from gnomAD (in case of human proteins). In-house developed CATH-FunVar (Functional Variation) pipeline was used to extract all annotations on known and predicted functional sites. For the missense coding variants from gnomAD, the impact of binding affinity of the complex was analysed using mCSM-ppi2 program. Affinity-enhancing variants analysed using functional sites, and population data from gnomAD. The human proteins predicted to contain affinity-enhancing variants are used for pathway enrichment and identification of CATH functional families (CATH-FunFams) linked with small molecules/drugs from ChEMBL</p></caption><graphic xlink:href="EMS190885-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>The structure of human TOMM70 in complex with SARS-CoV-2 ORF9b [PDB ID: 7KDT].</title><p>(A) ORF9b-TOMM70 complex: SARS-CoV-2 ORF9b (blue) interacts with the C-terminal domain of human TOMM70 (tan). ORF9b binds at the substrate-binding pocket in TOMM70. The structural locations of variants (with ΔΔG<sup>Affinity</sup> <underline>&gt;</underline> 0.5 Kcal/mol) are shown in red. These include three DC-variants (V556L, K576R, A591T) and two DCSS-variants (V514I, A483T). (B) The structural impact of DC-variants on atomic interactions at the interface, are shown. HP: Hydrophobic (green), H-bond: hydrogen bond (red), VDW: Van-der-Waals (blue), Polar (orange) (C) Effects of affinity-enhancing variants in TOMM70 are shown in detail (figures in 2C source: mCSM-PPI2).</p></caption><graphic xlink:href="EMS190885-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>IFIH1-PLpro complex built using AlphaFold2-multimer.</title><p>(A) Human IFIH1 is shown in tan and SARS-CoV-2:PLpro is shown in blue. The structural locations of affinity-enhancing variants (ΔΔG<sup>Affinity</sup> <underline>&gt;</underline> 0.5 Kcal/mol) are shown in red. These include three DC-variants (S16L, Y13N) (B, C) The structural impact of DC-variants on atomic interactions at the interface, are shown. (C) Effects of affinity-enhancing variants in TOMM70 are shown in detail (figures in 2B and 2C from mCSM-PPI2). HP: Hydrophobic (green), H-bond: hydrogen bond (red), VDW: Van-der-Waals (blue), Polar (orange).</p></caption><graphic xlink:href="EMS190885-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>SARS-CoV-2: PLpro-human ISG15 complex (7RBS).</title><p>(A) Human ISG15 (blue) in complex with SARS-CoV-2: PLpro (tan). The affinity-enhancing variants L121N and S21N are indicated in red. (B) The table summarizes the impact of affinity-enhancing mutations (wild type vs mutant) on atomic interactions at the interface. Atomic interactions associated with L121Q and S21N are shown in (C). HP: Hydrophobic (green), H-bond: hydrogen bond (red), VDW: Van-der-Waals (blue), Polar (orange)</p></caption><graphic xlink:href="EMS190885-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>The mode of SARS-CoV-2:PLpro in complex with human:IFIT2, and mapping of affinity-enhancing variants</title><p><bold>(A)</bold> Mapping of the affinity-enhancing variants (red) K221E, A319S/T, L373F, Y383F onto the IFIT2 (cornflower blue)-Sars-CoV-2:PLpro (tan) complex. <bold>(B)</bold> PLpro interacts with IFIT2 at a site which partially overlaps with a known RNA-binding region (yellow).</p></caption><graphic xlink:href="EMS190885-f005"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Summary of human: SARS-CoV-2 protein complexes used for the study.</title><p>The table lists 3D complexes used in this study. We outline the source, quality metrics such as Interface pLDDT (<underline>&gt;</underline>70), Interface PAE (<underline>&lt;</underline>10), PIZSA Interface stability Z-score (<underline>&gt;</underline>1.5 indicates stable interface) and PRODIGY binding energy (ΔG <underline>&lt;</underline> -4.3 Kcal/Mol, cutoff chosen based on experimental binding energy values reported in PRODIGY reference. The literature supporting biochemical evidence of protein/domain interaction is also cited in <xref ref-type="supplementary-material" rid="SD1">Supplementary file 2</xref>. For modelled complexes, we first built models using both the AlphaFold2 (ptm method) or AlphaFold2-multimer(v1) and then selected model from one of these methods, whichever had the best interface quality.</p></caption><table frame="box" rules="all"><thead><tr><th valign="middle" align="center">SARS-CoV-2 protein</th><th valign="middle" align="center">Human protein interactor</th><th valign="middle" align="center">Source of Complex</th><th valign="middle" align="center">Interface pLDDT score</th><th valign="middle" align="center">Interface PAE score</th><th valign="middle" align="center">PIZSA Interface stability Z-score (≥ 1.5 = stable)</th><th valign="middle" align="center">PRODIGY ΔG Kcal/mol)</th></tr></thead><tbody><tr><td valign="middle" align="center">ORF9b</td><td valign="middle" align="center">TOMM70</td><td valign="middle" align="center">PDB [ID:7KDT]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">2.507</td><td valign="middle" align="center">-17.4</td></tr><tr><td valign="middle" align="center">NSP1</td><td valign="middle" align="center">RPS2</td><td valign="middle" align="center">PDB [ID: 6ZMT]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">2.283</td><td valign="middle" align="center">-4.6</td></tr><tr><td valign="middle" align="center">NSP1</td><td valign="middle" align="center">RPS3</td><td valign="middle" align="center">PDB [ID: 6ZMT]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">2.805</td><td valign="middle" align="center">-4.5</td></tr><tr><td valign="middle" align="center">Spike-RBD</td><td valign="middle" align="center">ACE2</td><td valign="middle" align="center">PDB [ID:6M0J]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">2.582</td><td valign="middle" align="center">-11.9</td></tr><tr><td valign="middle" align="center">ORF6</td><td valign="middle" align="center">NUP98</td><td valign="middle" align="center">PDB [ID: 7VPH]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">2.780</td><td valign="middle" align="center">-6.1</td></tr><tr><td valign="middle" align="center">ORF6</td><td valign="middle" align="center">RAE1</td><td valign="middle" align="center">PDB [ID: 7VPH]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">2.161</td><td valign="middle" align="center">-8.8</td></tr><tr><td valign="middle" align="center">ORF3a</td><td valign="middle" align="center">APOA1</td><td valign="middle" align="center">PDB [ID: 7KJR]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">2.569</td><td valign="middle" align="center">-15.6</td></tr><tr><td valign="middle" align="center">E</td><td valign="middle" align="center">PASL1</td><td valign="middle" align="center">PDB[ID:7M4R]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">1.685</td><td valign="middle" align="center">-6.6</td></tr><tr><td valign="middle" align="center">PLPro</td><td valign="middle" align="center">ISG15</td><td valign="middle" align="center">PDB[ID:7RBS]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">2.046</td><td valign="middle" align="center">-13.4</td></tr><tr><td valign="middle" align="center">PLPro</td><td valign="middle" align="center">UBB</td><td valign="middle" align="center">PDB[ID:7RBR]</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">n/a</td><td valign="middle" align="center">2.424</td><td valign="middle" align="center">-10.4</td></tr><tr><td valign="middle" align="center">PLPro</td><td valign="middle" align="center">IFIT2</td><td valign="middle" align="center">AlphaFold2-ptm</td><td valign="middle" align="center">72.82</td><td valign="middle" align="center">9.86</td><td valign="middle" align="center">2.460</td><td valign="middle" align="center">-11.3</td></tr><tr><td valign="middle" align="center">PLPro</td><td valign="middle" align="center">IFIH1</td><td valign="middle" align="center">AlphaFold2-multimer(v1)</td><td valign="middle" align="center">83.00</td><td valign="middle" align="center">10.00</td><td valign="middle" align="center">2.375</td><td valign="middle" align="center">-10.1</td></tr><tr><td valign="middle" align="center">N</td><td valign="middle" align="center">TRIM25</td><td valign="middle" align="center">AlphaFold2-ptm</td><td valign="middle" align="center">93.15</td><td valign="middle" align="center">2.87</td><td valign="middle" align="center">2.24</td><td valign="middle" align="center">-9.1</td></tr><tr><td valign="middle" align="center">NSP7</td><td valign="middle" align="center">SCRB1</td><td valign="middle" align="center">AlphaFold2-multimer(v1)</td><td valign="middle" align="center">83.87</td><td valign="middle" align="center">4.27</td><td valign="middle" align="center">2.144</td><td valign="middle" align="center">-8.0</td></tr><tr><td valign="middle" align="center">Spike-RBD</td><td valign="middle" align="center">KREMEN1</td><td valign="middle" align="center">AlphaFold2-ptm</td><td valign="middle" align="center">81.02</td><td valign="middle" align="center">4.74</td><td valign="middle" align="center">2.148</td><td valign="middle" align="center">-10.2</td></tr><tr><td valign="middle" align="center">NSP15</td><td valign="middle" align="center">ARF6</td><td valign="middle" align="center">AlphaFold2-ptm</td><td valign="middle" align="center">82.61</td><td valign="middle" align="center">7.20</td><td valign="middle" align="center">2.063</td><td valign="middle" align="center">-7.5</td></tr><tr><td valign="middle" align="center">NSP14</td><td valign="middle" align="center">TRIMM</td><td valign="middle" align="center">AlphaFold2-ptm</td><td valign="middle" align="center">81.24</td><td valign="middle" align="center">7.58</td><td valign="middle" align="center">1.974</td><td valign="middle" align="center">-8.8</td></tr><tr><td valign="middle" align="center">Spike-NTD</td><td valign="middle" align="center">AXL</td><td valign="middle" align="center">AlphaFold2-ptm</td><td valign="middle" align="center">75.31</td><td valign="middle" align="center">8.55</td><td valign="middle" align="center">2.321</td><td valign="middle" align="center">-10.6</td></tr><tr><td valign="middle" align="center">ORF7b</td><td valign="middle" align="center">UN93B</td><td valign="middle" align="center">AlphaFold2-ptm</td><td valign="middle" align="center">72.77</td><td valign="middle" align="center">9.45</td><td valign="middle" align="center">2.488</td><td valign="middle" align="center">-5.1</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>14 Human proteins with variants predicted to have significant impact on binding affinity to SARS-CoV-2 interactor proteins (by mCSM-PPI2 program [<xref ref-type="bibr" rid="R55">55</xref>]).</title><p>The first column lists the name of complexes in the following format-human protein (SARS-CoV-2 interactor protein). For every complex, the variants in human proteins that are predicted to enhance binding affinity with ΔΔG<sup>Affinity</sup> score <underline>&gt;</underline>0.5 Kcal/mol are indicated in bold. The variants that are predicted to increase binding affinity but with lower scores ranging from 0 &lt; ΔΔG &lt; 0.49 Kcal/mol are provided in the last column. <sup>*</sup> Indicates that the ACE2 variants reported in our study are also noted to enhance binding affinity in previous studies [reviewed in 45].</p></caption><table frame="box" rules="all"><thead><tr><th valign="middle" align="center">Name of the complex: human (SARS-CoV-2 protein)</th><th valign="middle" align="center">Affinity-enhancing variants in human proteins (ΔΔG<sup>Affinity</sup> ≥ 0.5 kcal/mol) (Stabilizing mutations)</th><th valign="middle" align="center">Affinity-reducing variants in human proteins (ΔΔG<sup>Affinity</sup> &lt; -0.5 kcal/mol) (de-stabilizing mutations)</th><th valign="middle" align="center">Other affinity-enhancing variants in human proteins (0 &lt; ΔΔG &lt; 0.49 Kcal/mol)</th></tr></thead><tbody><tr><td valign="middle" align="left">hTOMM70 (ORF9B)</td><td valign="middle" align="center"><bold>V556L, K576R, A591T, V514I, A483T</bold></td><td valign="middle" align="center">I412T, Q477G, H515Q, L584M, I 554T, D589N, L111P, F155L, G530S, D397N</td><td valign="middle" align="center">A582V</td></tr><tr><td valign="middle" align="left">hISG15 (PLPro)</td><td valign="middle" align="center"><bold>L121Q</bold></td><td valign="middle" align="center">L60V, G128V, L28M, F122L, P130T, E127G, M23V, N151D, L85P, M23T, R155W,N151K, R155Q</td><td valign="middle" align="center">S21N, Q55R, Q118R,V148L,A30V,D56Y, Q31H</td></tr><tr><td valign="middle" align="left">hIFIH1 (PLpro)</td><td valign="middle" align="center"><bold>Y13N, S16L</bold></td><td valign="middle" align="center">-</td><td valign="middle" align="center">L120F, F107S, L121F, M95</td></tr><tr><td valign="middle" align="left">hIFIT2 (PLpro)</td><td valign="middle" align="center"><bold>L373F, K221E, A319S, A319T, L373F, Y383F</bold></td><td valign="middle" align="center">N300K, R376Q, R406S, L375V, R376P, Q384K, L323P, G398V, F380L</td><td valign="middle" align="center">Q381H, R292K, P190Q, A391V</td></tr><tr><td valign="middle" align="left">hRPS3 (NSP1)</td><td valign="middle" align="center"><bold>V164I, I99F</bold></td><td valign="middle" align="center">R106C, L86H, Y34H, V153A</td><td valign="middle" align="center">E81Q, A52T, I223V, A114P,</td></tr><tr><td valign="middle" align="left">hNUP98-hRAE1(ORF6)</td><td valign="middle" align="center"><bold>NUP98: T190S RAE1: A275V</bold></td><td valign="middle" align="center">-</td><td valign="middle" align="center">NUP98: K185R, I162V. RAE1: 275-CANCER, S311L</td></tr><tr><td valign="middle" align="left">hARF6 (NSP15)</td><td valign="middle" align="center"><bold>L166F</bold></td><td valign="middle" align="center">I29V, L33V, Y78C</td><td valign="middle" align="center">N56H, D68H, I96F</td></tr><tr><td valign="middle" align="left">hTRIM25 (N)</td><td valign="middle" align="center"><bold>A466T</bold></td><td valign="middle" align="center">V470M, F615L</td><td valign="middle" align="center">C475Y, P490L, I457V, A471S, K458E, C506S</td></tr><tr><td valign="middle" align="left">hTRIMM (NSP14)</td><td valign="middle" align="center"><bold>I105F</bold></td><td valign="middle" align="center">-</td><td valign="middle" align="center">Q160R, H223Y, K146R, A144E, I13F</td></tr><tr><td valign="middle" align="left">hAXL (spike-NTD)</td><td valign="middle" align="center"><bold>V38M</bold></td><td valign="middle" align="center">L54Il, Q57K</td><td valign="middle" align="center">A79E</td></tr><tr><td valign="middle" align="left">hKremen1 (Spike-RBD)</td><td valign="middle" align="center"><bold>Y66H, V189L</bold></td><td valign="middle" align="center">Y98C, C200Y, C86Y, E187K, V93M, E187K, V93M, H196L, Y167C, Y107H, G166D, W108R</td><td valign="middle" align="center">-</td></tr><tr><td valign="middle" align="left">hACE2 (spike-RBD)</td><td valign="middle" align="center"><bold>G326E*</bold></td><td valign="middle" align="center">G352V, D355N, L585P</td><td valign="middle" align="center">A501T*, K26R*, S19P*, K26E*</td></tr><tr><td valign="middle" align="left">hPALS1(E)</td><td valign="middle" align="center"><bold>L321F</bold></td><td valign="middle" align="center">-</td><td valign="middle" align="center">-</td></tr></tbody></table></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Details of variants in TOMM70 that impact binding to ORF9b.</title><p>For each variant, SNP ID (i.e. rsID), amino acid mutation, mCSM-PPI2 prediction, functional site annotations and population in gnomAD (in which these variants are present) are indicated. Functional sites are abbreviated as follows-DC_PPI: directly contacting interface site, DCSS_PPI, secondary shell residue from the DC interface site, Ligsite: indicates occurrence in a known ligand binding site and near_ligsite indicates sites that are proximal to a known ligand (HSP90) binding site. Variants with Mutpred2 pathogenicity score <underline>&gt;</underline> 0.50, are indicated.</p></caption><table frame="box" rules="all"><thead><tr><th valign="middle" align="left">Variant ID</th><th valign="middle" align="center">rsID</th><th valign="middle" align="center">Missense variant in gnomAD</th><th valign="middle" align="center">mcsm-ppi2-prediction (kcal/mol)</th><th valign="middle" align="center">Functional site annotation</th><th valign="middle" align="center">GnomAD populations [and their allele frequency -AF]</th></tr></thead><tbody><tr><td valign="middle" align="left">3-100086895-C-T</td><td valign="middle" align="center">rs1306989616</td><td valign="middle" align="center">p.Val556Leu</td><td valign="middle" align="center"><bold>0.905</bold></td><td valign="middle" align="center">DC_PPI</td><td valign="middle" align="center">African/AA [AF: 0.00007]</td></tr><tr><td valign="middle" align="left">3-100084508-T-C</td><td valign="middle" align="center">rs1370508158</td><td valign="middle" align="center">p.Lys576Arg</td><td valign="middle" align="center"><bold>0.618</bold></td><td valign="middle" align="center">DC_ PPI Mutpred2_0.58</td><td valign="middle" align="center">South Asian [0.00003]</td></tr><tr><td valign="middle" align="left">3-100084464-C-T</td><td valign="middle" align="center">rs756063544</td><td valign="middle" align="center">p.Ala591Thr</td><td valign="middle" align="center"><bold>0.599</bold></td><td valign="middle" align="center">DC_PPI Mutpred2_0.53</td><td valign="middle" align="center">Latino/AA [0.00008] AFR [0.00004] Other [ 0.0001]</td></tr><tr><td valign="middle" align="left">3-100087892-C-T</td><td valign="middle" align="center">rs957967770</td><td valign="middle" align="center">p.Val514Ile</td><td valign="middle" align="center"><bold>0.562</bold></td><td valign="middle" align="center">DCSS_ PPI Mutpred2_0.60</td><td valign="middle" align="center">Latino/AA [0.0001] European (non-Finnish [0.00003]</td></tr><tr><td valign="middle" align="left">3-100091455-C-T</td><td valign="middle" align="center">rs770985289</td><td valign="middle" align="center">p.Ala483Thr</td><td valign="middle" align="center"><bold>0.499</bold></td><td valign="middle" align="center">DCSS_ PPI Mutpred2_0.90</td><td valign="middle" align="center">European (non-Finnish) [0.00002] Latino/AA [0.00002]</td></tr><tr><td valign="middle" align="left">3-100092482-A-G</td><td valign="middle" align="center">rs1266227924</td><td valign="middle" align="center">p.Ile412Thr</td><td valign="middle" align="center">-1.054</td><td valign="middle" align="center">DC_ PPI</td><td valign="middle" align="center">African/AA [0.00008]</td></tr><tr><td valign="middle" align="left">3-100091472-T-C</td><td valign="middle" align="center">rs750026792</td><td valign="middle" align="center">p.Glu477Gly</td><td valign="middle" align="center">-1.014</td><td valign="middle" align="center">DC_ PPI</td><td valign="middle" align="center">South Asian [0.000032]</td></tr><tr><td valign="middle" align="left">3-100105815-A-G</td><td valign="middle" align="center">rs765666545</td><td valign="middle" align="center">p.Leu111Pro</td><td valign="middle" align="center">-1.056</td><td valign="middle" align="center">near_ligsite</td><td valign="middle" align="center">European (non-Finnish) [0.000008]</td></tr><tr><td valign="middle" align="left">3-100084470-C-T</td><td valign="middle" align="center">rs753612125</td><td valign="middle" align="center">p.Asp589Asn</td><td valign="middle" align="center">-0.534</td><td valign="middle" align="center">DCSS_ PPI</td><td valign="middle" align="center">African/AA[0.0000615]; South Asian [0.00003]</td></tr><tr><td valign="middle" align="left">3-100086973-C-T</td><td valign="middle" align="center">rs775872768</td><td valign="middle" align="center">p.Gly530Ser</td><td valign="middle" align="center">-0.545</td><td valign="middle" align="center">-</td><td valign="middle" align="center">South Asian [0.00003]</td></tr><tr><td valign="middle" align="left">3-100093900-C-T</td><td valign="middle" align="center">rs762230068</td><td valign="middle" align="center">p.Asp397Asn</td><td valign="middle" align="center">-0.536</td><td valign="middle" align="center">-</td><td valign="middle" align="center">African/AA [0.0001] European (non-Finnish) [0.000008]</td></tr></tbody></table></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Details of variants in human ISG15 that impact binding to SARS-CoV-2:PLpro.</title><p>For each variant, SNP ID, amino acid mutation, mCSM-PPI2 prediction, functional site annotations and enrichment in specific population in gnomAD are indicated. Functional sites are abbreviated as follows-DC_PPI: directly contacting interface site, DCSS_PPI, secondary shell residue, ligsite: known ligand binding site, near_ Scorecon90: proximity to conserved sites predicted using Scorecons (score <underline>&gt;</underline> 90). Variants with Mutpred2 pathogenicity score &gt;0.50 are listed.</p></caption><table frame="box" rules="all"><thead><tr><th valign="middle" align="left" style="background-color:#d9d9d9">rsIDs</th><th valign="middle" align="center" style="background-color:#d9d9d9">Mutation</th><th valign="middle" align="center" style="background-color:#d9d9d9">Mcsm-PPI2 (kcal/mol)</th><th valign="middle" align="center" style="background-color:#d9d9d9">Functional site annotations</th><th valign="middle" align="center" style="background-color:#d9d9d9">Populations in gnomAD and [Allele frequency]</th></tr></thead><tbody><tr><td valign="middle" align="left">rs748715915</td><td valign="middle" align="center">p.Leu121Gln</td><td valign="middle" align="center"><bold>0.57</bold></td><td valign="middle" align="center">DC-PPI, Near_SC90 Near_LRGG motif</td><td valign="middle" align="center">NFE-SWEDISH [0.00003834]</td></tr><tr><td valign="middle" align="left">rs143888043</td><td valign="middle" align="center">p.Ser21Asn</td><td valign="middle" align="center"><bold>0.401</bold></td><td valign="middle" align="center">DC-PPI</td><td valign="middle" align="center">AFR [0.01648] *also supported by GenomeAsia1000K AMR[0.0008475], NFE [0.00007794], SAS[0.00009810], other[0.0008333]</td></tr><tr><td valign="middle" align="left">rs1477663018</td><td valign="middle" align="center">Leu85Pro</td><td valign="middle" align="center">-1.002</td><td valign="middle" align="center">DCSS-PPI, Scorecons90</td><td valign="middle" align="center">NFE-North-Western [0.00002404]</td></tr><tr><td valign="middle" align="left">rs1160940574</td><td valign="middle" align="center">p.Met23Thr</td><td valign="middle" align="center">-1.017</td><td valign="middle" align="center">DC-PPI</td><td valign="middle" align="center">NFE-North-Western [0.00002387]</td></tr><tr><td valign="middle" align="left">rs761507082</td><td valign="middle" align="center">p.Arg155Trp</td><td valign="middle" align="center">-1.166</td><td valign="middle" align="center">DC-PPI LRGG motif site</td><td valign="middle" align="center">AMR[0.0004058] ASJ[0.0001011], SAS[0.00003275],</td></tr><tr><td valign="middle" align="left">rs774241776</td><td valign="middle" align="center">p.Asn151Lys</td><td valign="middle" align="center">-1.286</td><td valign="middle" align="center">DC-PPI Near_ Scorecon90</td><td valign="middle" align="center">Other [0.0001647]</td></tr><tr><td valign="middle" align="left">rs750338976</td><td valign="middle" align="center">p.Arg155Gln</td><td valign="middle" align="center">-2.061</td><td valign="middle" align="center">DC-PPI LRGG motif site</td><td valign="middle" align="center">NFE[0.00001808]</td></tr></tbody></table></table-wrap><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Details of affinity-enhancing variants in variants in IFIT2 (PLpro interacting protein).</title><p>For each variant, SNP ID, amino acid mutation, mCSM-PPI2 prediction, functional site annotations and enrichment in specific population in gnomAD are indicated. Functional sites are abbreviated as follows-DC_PPI: means directly contacting interface site, DCSS_PPI, secondary shell residue, ligsite: indicates known ligand binding site (i.r. TNA binding site in IFIT2) and near_ligsite indicates sites that are proximal to a known ligand binding site. near_Scorecon90: proximity to conserved sites predicted using Scorecons (score &gt; 90).</p></caption><table frame="box" rules="all"><thead><tr><th valign="middle" align="left" style="background-color:#d9d9d9">Variant ID</th><th valign="middle" align="center" style="background-color:#d9d9d9">rsID</th><th valign="middle" align="center" style="background-color:#d9d9d9">Mutation</th><th valign="middle" align="center" style="background-color:#d9d9d9">Mcsm-PPI2 (kcal/mol)</th><th valign="middle" align="center" style="background-color:#d9d9d9">Functional site annotations</th><th valign="middle" align="center" style="background-color:#d9d9d9">Populations in gnomAD [: Allele frequency]</th></tr></thead><tbody><tr><td valign="middle" align="left">10-91066830-C-T</td><td valign="middle" align="center">rs761596604</td><td valign="middle" align="center">p.Leu373 Phe</td><td valign="middle" align="center"><bold>0.911</bold></td><td valign="middle" align="center">DCSS</td><td valign="middle" align="center">South Asian [0.00003268] Asian: 0.00004 (allofus)</td></tr><tr><td valign="middle" align="left">10-91066374-A-G</td><td valign="middle" align="center">rs1305223950</td><td valign="middle" align="center">p.Lys221 Glu</td><td valign="middle" align="center"><bold>0.616</bold></td><td valign="middle" align="center">DCSS Near_ligsite Near_Scorecon90</td><td valign="middle" align="center">South Asian [0.00003268] Asian: 0.00002 (AllofUs)</td></tr><tr><td valign="middle" align="left">10-91066668-G-T</td><td valign="middle" align="center">rs775027680</td><td valign="middle" align="center">p.Ala319 Ser</td><td valign="middle" align="center"><bold>0.532</bold></td><td valign="middle" align="center">DCSS Near_ligsite Near_Scorecon90</td><td valign="middle" align="center">African/African American [0.00006460]</td></tr><tr><td valign="middle" align="left">10-91066668-G-T</td><td valign="middle" align="center">rs775027680</td><td valign="middle" align="center">p.Ala319 Thr</td><td valign="middle" align="center"><bold>0.516</bold></td><td valign="middle" align="center">DCSS Near_ligsite Near_ Scorecon90</td><td valign="middle" align="center">African/African American [0.00006460] East Asian: 0.00007130 Latino/Admixed American [0.00007008] Swedish [0.00003832]</td></tr><tr><td valign="middle" align="left">10-91066861-A-T</td><td valign="middle" align="center">rs751422356</td><td valign="middle" align="center">p.Tyr383Phe</td><td valign="middle" align="center"><bold>0.449</bold></td><td valign="middle" align="center">Near_ligsite</td><td valign="middle" align="center">European NFE [0.00001556]</td></tr></tbody></table></table-wrap><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><title>Top significant GO, KEGG and Reactome pathways associated with 14 SARS-CoV-2-interacting human proteins (containing affinity-enhancing variants).</title></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="left">Term</th><th valign="middle" align="center">Pathway</th><th valign="top" align="left">Adj. p-value</th></tr></thead><tbody><tr><td valign="top" align="left">REAC:R-HSA-9694516</td><td valign="top" align="left">SARS-CoV-2 Infection</td><td valign="top" align="left">2.59x10<sup>-8</sup></td></tr><tr><td valign="top" align="left">GO:1903900</td><td valign="top" align="left">regulation of viral life cycle</td><td valign="top" align="left">3.19x10<sup>-5</sup></td></tr><tr><td valign="top" align="left">KEGG:05164</td><td valign="top" align="left">Influenza A</td><td valign="top" align="left">0.0019</td></tr></tbody></table></table-wrap><table-wrap id="T7" orientation="portrait" position="float"><label>Table 7</label><caption><title>Human proteins with CATH-FunFams containing small molecule inhibitors.</title><p>Three human proteins (IFIH1, AXL and ARF6) are observed to be linked with small molecule inhibitors from ChEMBL. The associated entries in ChEMBL are indicated. The representative 3D structure for each functional families in CATH is indicated. If the representative is not available in CATH, the representative from PDB is shown.</p></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="center">Protein</th><th valign="top" align="center">CATH superfamily and functional family (CATH-FunFam) ID</th><th valign="top" align="center">Associated entry in ChEMBL</th><th valign="top" align="center">Representative 3D-structure</th></tr></thead><tbody><tr><td valign="top" align="center">IFIH1</td><td valign="top" align="center">1.10.533.10 CATH-FunFam ID 77</td><td valign="top" align="center">CHEMBL4739862 [CHEMBL4594258, phase 2]</td><td valign="top" align="center">7DNI [PDB]</td></tr><tr><td valign="top" align="center">AXL</td><td valign="top" align="center">2.60.40.10 CATH-FunFam ID 810</td><td valign="top" align="center">CHEMBL4895 [CHEMBL3301622, approved] CHEMBL4879451</td><td valign="top" align="center">5vxzD00 [CATH]</td></tr><tr><td valign="top" align="center">ARF6</td><td valign="top" align="center">3.40.50.300 CATH-FunFam ID 286</td><td valign="top" align="center">CHEMBL5987 CHEMBL1075274,</td><td valign="top" align="center">3lvrE04 [CATH]</td></tr></tbody></table></table-wrap></floats-group></article>